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I. INTRODUCTION 
Osteoporosis is a common disease of postmenopausal women and the elderly. 
Around 1/3 of all postmenopausal women suffer from osteoporosis due to falling 
estrogen levels in age. It results in reduced bone mineral density and leads to an 
increased risk of fractures. Normally, the bone mass of healthy adults is kept 
constant by a balance between constant bone formation and bone resorption. In 
patients with osteoporosis this mechanism is impaired, leading to decreased bone 
mass. As a consequence, life quality for these patients is also impaired. 
Furthermore, even small accidents are likely to cause fractures, especially of 
wrist, hip or spine, leading to immobility, while pain in the destabilized bones 
itself, especially in the spine is the reason for reduced mobility, accelerating bone 
resorption even more (HTTP://WWW.IOFBONEHEALTH.ORG/). Treatment 
costs are expected to rise even more in the coming years; in Germany alone, the 
estimated costs in the year 2010 were around 9 billion €, which are estimated to 
rise up to more than 11 billion € by the year 2025 due to an aging population 
(SVEDBOM et al., 2013). The medications approved for the prevention and 
treatment of osteoporosis are divided into the two categories, anti-resorptive and 
anabolic (JOHN M. EISENBERG CENTER FOR CLINICAL DECISIONS AND 
COMMUNICATIONS SCIENCE, 2007). Like all medicals there are side effects 
and additionally, patients often stop their treatment after only one year  
(HTTP://WWW.IOFBONEHEALTH.ORG/).  On the one hand, this phenomenon 
is due to the side effects, but there are also many other factors like complex 
dosing schemes etc. (HERNLUND et al., 2013). 
Given the fact that the population will be aging the coming years and the risk of 
suffering from osteoporosis will be rising, new and improved treatment options 
must be developed. To achieve this aim, the complex mechanisms involved in bone 
homeostasis which are not yet fully understood, have to be examined. 
Over the last decade there has been quite a progress in bone metabolism research. 
Examples include the discovery that the Wnt-pathway influences osteoblast 
formation (WESTENDORF et al., 2004), or the identification of RANKL and OPG 
as the main mediators on osteoclastogenesis (NAKAGAWA et al., 1998). There is 
also accumulating evidence that the epidermal growth factor receptor (EGFR) also 
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plays an important role in bone metabolism (SCHNEIDER et al., 2009b). It has 
been known that it participates in many developmental processes like growth, 
proliferation and differentiation of skeletal tissues (XIAN, 2007) and mediates the 
anabolic actions of PTH, which is used as the only anabolic agent for osteoporosis 
treatment (POOLE & REEVE, 2005). 
The aim of this study was to examine the effect of bone-specific over-expression of 
amphiregulin (AREG), a ligand of the EGFR. The Areg transcript had been detected 
by microarray analysis to be up-regulated after intermittent PTH treatment (QIN et 
al., 2005). Therefore, Areg might be one of the genes involved in mediating the 
anabolic effect of intermittent PTH treatment. 
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II. REVIEW OF THE LITERATURE 
1. Bone metabolism and osteoporosis  
1.1. Bone development 
1.1.1. Endochondral and intramembranous ossification 
The skeleton is the scaffold of our body and is characterized by an enormous 
complexity as it comprises many differently shaped bones with varying amounts of 
calcified bone and cartilage. Although it has long been considered a quite static 
tissue its capability for healing and remodeling is enormous, and it serves as a 
mineral depot that is able to release its contents quickly on metabolic demand 
(SOMMERFELDT & RUBIN, 2001). Bone has its origin in three embryonic 
lineages: the craniofacial skeleton is derived from cranial neural crest cells, the axial 
skeleton from paraxial mesoderm (somites) and the limb skeleton from lateral plate 
mesodermal cells (OLSEN et al., 2000).  
There are two possible ways of bone development: endochondral and 
intramembranous ossification. Both ways share the first step of forming a 
mesenchymal template. Most bones are then built by endochondral ossification, 
where chondroblasts, derived from mesenchymal cells form a chondral scaffold 
which will be replaced by calcified bone. Only few bones, as the mandibles, the 
clavicles and certain bones of the skull (DUCY et al., 2000) are built without this 
cartilaginous frame and are formed directly on the mesenchymal template by 
intramembranous ossification.  
1.1.2. Osteoblasts and osteoclasts 
There are three different cell types which can be distinguished in bone: the bone-
destroying osteoclasts, the bone-forming osteoblasts and osteocytes, the final 
differentiation stage of the osteoblast (SOMMERFELDT & RUBIN, 2001). 
Osteoblasts have their origin in mesenchymal stem cells (AUBIN, 1998), while the 
multinucleated osteoclasts originate from hematopoietic stem cells, their precursors 
descending from monocytes (FUJIKAWA et al., 1996). 
The differentiation of osteoblasts is very complex, requiring several transcription 
factors and growth factors like CBFA1 / RUNX2 and OSX, the main transcription 
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factors for osteoblast differentiation (DUCY et al., 2000), and involving different 
pathways like the Wnt-pathway or the Notch-pathway, for example (LONG, 2012). 
Osteoblasts synthesize osteoid, an organic matrix consisting mainly of collagen I 
and to a lesser extent proteoglycans and other proteins like signal molecules, which 
play an important role in bone homeostasis (SOMMERFELDT & RUBIN, 2001). 
This primary network will then be mineralized by deposition of mineral crystals, 
calcium and phosphate, forming hydroxyapatites (TITORENCU et al., 2013), the 
main components of the mineralized bone matrix. Some of the osteoblasts further 
differentiate to osteocytes, which become trapped in the mineralized matrix, 
forming dendrite connections between them which enable cell-to-cell 
communication (BONEWALD, 2011). 
Osteoclasts are multinucleated cells, formed by the fusion of progenitors of 
monocytes/macrophages (TEITELBAUM, 2000). Certain molecules like M-CSF 
and RANKL are essential for osteoclastogenesis (FELIX et al., 1990; 
NAKAGAWA et al., 1998; KARSENTY & WAGNER, 2002), whereas OPG 
inhibits osteoclastogenesis (SIMONET et al., 1997). It has been shown that the 
differentiation of the osteoclast to the final stage of the bone-resorbing “expert” 
requires not only factors secreted mainly (but not exclusively) by osteoblasts but 
also direct cell-to-cell contact with them and marrow stromal cells (UDAGAWA et 
al., 1990; TEITELBAUM, 2000). On bone contact, the osteoclast forms a “ruffled” 
membrane, resorbing calcified bone matrix by secretion of several acidifying 
molecules (TEITELBAUM & ROSS, 2003).  
This interaction between bone-forming and bone-resorbing cells indicates a 
complex system between constant bone formation and bone resorption. Any 
disturbances of this balance may lead to severe diseases of the skeletal system, 
resulting in either increased (osteopetrosis) or decreased bone mass (osteoporosis). 
1.2. Osteoporosis and treatment options 
„A systemic skeletal disease characterized by low bone mass and microarchitectural 
deterioration of bone tissue with a consequent increase in bone fragility and 
susceptibility to fracture” is the internationally agreed definition for osteoporosis 
(CONFERENCE, 1993; KANIS et al., 2008). This definition captures the main 
“symptom” of osteoporosis: low bone mass. At first, low bone mass alone does not 
cause any clinical symptoms, but it results in an increased fracture risk, leading not 
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only to high treatment costs when fractures occur, but also to an increased mortality, 
especially for patients who suffer from hip fractures (JOHNELL & KANIS, 2005). 
Therefore several screening tools have been developed to estimate the fracture risk 
of patients (RUBIN et al., 2013). On the basis of these tools, fracture risks are 
estimated and suitable treatment options are applied. Basically, treatment options 
are available as drugs which can act anti-resorptive (calcium, vitamin D, hormone 
therapy, bisphosphonates, selective estrogen-receptor modulators, and calcitonin) 
or anabolics (parathyroid hormone, as “Teriparatide”), or a combination of both 
(Strontium ranelate, stimulates bone formation and avoids bone resorption) 
(SAMBROOK & COOPER, 2006). Recently, drugs have been developed that 
directly affect biological pathways involved in bone metabolism, such as 
Denosumab, an antibody against RANKL, that thus reduces osteoclast activity, and 
also antibodies which inhibit sclerostin (a protein synthesized by osteocytes, acting 
as an inhibitor of the Wnt-signaling pathway), thus having an anabolic effect on 
osteoblast formation (TELLA & GALLAGHER, 2013). As every patient with a 
potential risk to develop a fracture due to osteoporosis has to be treated individually, 
and available drugs have side effects which have to be taken into account, there is 
a constant search for new treatment options. Bisphosphonates for example, 
accumulate in the skeleton over time, are eliminated by the kidney, and are known 
to have side effects in patients with reduced renal function but there can be also 
unwanted effects on the cardiovascular system (ERIKSEN et al., 2014). With the 
prospect of aging populations and the fact that an increased fracture risk due to 
osteoporosis occurs mainly in the elderly (DENNISON et al., 2006), it is a main 
goal for researchers in this field to decrease this risk and therefore avoid the 
following costs. Another challenge is to overcome poor patient compliance, which 
is one of the main problems in osteoporosis treatment (HUYBRECHTS et al., 2006; 
HERNLUND et al., 2013).  Several factors seem to be important, including 
frequency of dosing, adverse events, relationship between patient-physician, etc. 
(HERNLUND et al., 2013), whereas simplicity of dosing seems to correlate with 
better compliance (CLAXTON et al., 2001). The novel agent Denosumab for 
example, which belongs to a new class of antiresorptives by acting as an antibody, 
has been proven to effectively increase bone mass density when given in a 6 months 
interval (BONE et al., 2011). But so far there is only one anabolic agent available 
for osteoporosis treatment: PTH. The greatest disadvantage of PTH is the need of 
daily administration (CANALIS, 2010).   
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1.2.1. PTH 
PTH, a 84 amino acid-long peptide hormone, that is secreted by the parathyroid 
gland, is one of the three main mediators responsible for blood-calcium-
homeostasis; the other two are calcitonin and 1,25-dihydroxyvitamin D. 
Physiologically, PTH has catabolic functions on bone. Decreasing blood calcium 
levels cause PTH to release calcium from bones by osteoclast stimulation and 
therefore bone resorption (MUNDY & GUISE, 1999). Interestingly, PTH has quite 
the reverse effect when given intermittently (GUNNESS-HEY & HOCK, 1984; 
DOBNIG & TURNER, 1995). This effect is used for the treatment of osteoporosis 
as described before. “Teriparatide” contains recombinant human PTH (amino acids 
1-34 of the N-terminal region of the 84 amino acids long peptide, which is the 
biological active region) and is used as an anabolic agent for osteoporosis therapy 
as it stimulates bone formation and increases bone mineral density (NEER et al., 
2001; TELLA & GALLAGHER, 2013), therefore reducing fracture risk 
effectively. It is largely unknown how this effect is mediated. PTH is known to 
influence the expression of several genes involved in bone homeostasis. For 
example, the expression of type 1 collagen, alkaline phosphatase, osteonectin (ON) 
and osteopontin (OPN) are decreased by PTH-stimulation, while the expression of 
genes like collagenase-3, tissue inhibitors of metalloproteinases (TIMPs), insulin-
like growth factor 1 (IGF-1), tissue-type plasminogen activator (tPA),  interleukin 
(IL)-6, and leukemia inhibitory factor are increased (SWARTHOUT et al., 2002). 
The expression of another potent factor for pre-osteoblast proliferation, fibroblast 
growth factor 2 (FGF-2) is also increased by PTH (SABBIETI et al., 2009). It could 
be shown by microarray analysis, that treatment of an osteoblast-like cell line, rat 
UMR 106-01, with PTH stimulated the expression of another gene: Areg, encoding 
amphiregulin, a ligand of the epidermal growth factor receptor (EGFR) (QIN et al., 
2003; QIN & PARTRIDGE, 2005; QIN et al., 2005). On the other hand, mice 
lacking Areg had less trabecular bone than wild-type animals (LUETTEKE et al., 
1999; QIN et al., 2005), which leads to the conclusion that the bone anabolic effect 
of PTH may be greatly influenced by the EGFR-system. 
1.3. EGF-Receptor system 
The EGFR-system comprises four structurally related receptors, ERBB1 (EGFR), 
ERBB2, ERBB3 and ERBB4, and seven growth factors that are able to activate the 
EGFR: epidermal growth factor (EGF), transforming-growth factor α (TGFA), 
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heparin-binding EGF-like growth factor (HBEGF), betacellulin (BTC), 
amphiregulin (AREG), epiregulin (EREG) and epigen (EPGN) (YARDEN & 
SLIWKOWSKI, 2001; HARRIS et al., 2003; SCHNEIDER & WOLF, 2009). 
 
 
Figure 1: Overview of the EGFR system 
Reprinted from Schneider et al., Trends in Endocrinology and Pathology, 20, 517-
524, (2009) with permission from Elsevier: 
i) Receptor dimers are formed upon ligand binding and initiating 
intracellular signaling cascades 
ii) Activation of EGFR via heterologous signals: here G-protein-coupled 
receptors (GPCRs) and 
iii) other receptor tyrosine kinases (RTKs) 
These receptors belong to the family of receptor tyrosine kinases, and include an 
extracellular ligand-binding region, a single membrane-spanning domain, and a 
cytoplasmic protein tyrosine kinase-containing region which forms homo- or 
heterodimers after ligand-binding, causing autophosphorylation of the cytoplasmic 
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tyrosine residues (Figure 1) (YARDEN & SLIWKOWSKI, 2001; HOLBRO & 
HYNES, 2004).  These phosphorylated tyrosine residues serve as docking sites for 
intracellular signal molecules (OLAYIOYE et al., 2000), initiating multiple and 
complex signaling cascades essential for growth, differentiation, repair and survival 
of various tissues (ODA et al., 2005; YARDEN & SHILO, 2007). 
The ERBB-receptors are required for development, as demonstrated by the 
generation of mutant mouse lines lacking individual receptors:  
The EGFR (ERBB1) is an autonomous receptor, which is able to bind many ligands 
and form not only heterodimers but also homodimers (CITRI & YARDEN, 2006). 
EGFR knockout mice viability depends on their genetic background. In a 129/Sv 
background, mice are not viable and die at midgestation, due to a placental defect 
(SIBILIA et al., 2003), in a C57BL/6 background they die at birth and in MF1, C3H 
and CD 1 background some mice can reach an age of 20 days post partum 
(THREADGILL et al., 1995; SIBILIA et al., 2003). Several severe alterations of 
their phenotypes were observed, including alterations of the epithelium, the neural 
system and craniofacial malformations (MIETTINEN et al., 1995; SIBILIA & 
WAGNER, 1995; THREADGILL et al., 1995; MIETTINEN et al., 1999), leading 
to the early death of these knockout mice.  
Although ERBB2 cannot bind any ligands itself, it functions as the preferred partner 
for heterodimer-building (TZAHAR et al., 1996; CITRI & YARDEN, 2006). 
ERBB2 knockout mice die during embryonic development before E11 due to 
malformations of the heart, resulting in complete absence of heart trabeculae and 
therefore impaired heart function. Additionally severe alterations of the neural 
system could be found (LEE et al., 1995). 
Like ERBB2, ERBB3 itself is non-autonomous, but forms functional heterodimers 
with other ERBB-receptors (CITRI & YARDEN, 2006). ERBB3-deficient mice die 
around E13.5 also due to heart malformations. Those mice have a noticeably 
thinned heart wall and an insufficient valve function, resulting in blood reflux. In 
addition, these mice also show a hypoplastic cerebellar region (ERICKSON et al., 
1997). 
ERBB4 has similarities to ERBB1; it is an autonomous receptor which is able to 
bind to many ligands (CITRI & YARDEN, 2006). It is highly expressed in heart 
muscle and certain regions of the nervous system. ERBB4-deficient mice die 
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around E10.5; like in ERBB2 knockout mice, no heart trabeculae were detectable, 
leading to an impaired heart function and resulting in early lethality (GASSMANN 
et al., 1995). 
As mentioned above, knockout of the EGFR reduces life expectancy dramatically, 
and it is essential for the normal development of most tissues (MIETTINEN et al., 
1995; SIBILIA & WAGNER, 1995; MIETTINEN et al., 1999). It has been known 
for a long time that the EGFR-system plays also an important role in bone 
development, especially in bone formation (CANALIS & RAISZ, 1979; 
KUMEGAWA et al., 1983; NG et al., 1983; HATA et al., 1984; FANG et al., 1992; 
LOZA et al., 1995; CHIEN et al., 2000; QIN et al., 2005). Further studies showed 
that the EGFR promotes proliferation of bone-forming osteoblasts and inhibits their 
maturation and therefore mineralization of the bone (SIBILIA et al., 2003). On the 
other hand, transgenic mice overexpressing specific EGFR-ligands exhibit quite 
different bone phenotypes. Overexpression of EGF, for example, results in a 
reduced thickness of cortical bone due to accumulation of overproliferated 
osteoblasts in the endosteum and periosteum (CHAN & WONG, 2000), and mice 
overexpressing BTC are characterized by a high bone mass of the long bones 
(SCHNEIDER et al., 2009a). Transgenic mice overexpressing TGFA (JHAPPAN 
et al., 1990; SANDGREN et al., 1990) or HBEGF (PROVENZANO et al., 2005) 
on the other hand, showed no alterations of bone. For an overview of the influence 
of the EGFR network in bone cells see Figure 2. 
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Figure 2: Effect of EGFR network on bone cells 
Reprinted from Schneider et al., Trends in Endocrinology and Pathology, 20, 517-
524, (2009) with permission from Elsevier: 
a) Stimulation of proliferation of pre-chondrocytes and pre-osteoblasts via 
EGFR and inhibition of final differentiation 
b) Effect on pre-osteoclasts not fully understood, but stimulation of osteoclast 
differentiation via up-regulation of MCP1, MCSF, RANKL and down-
regulation of OPG 
 
1.4. Research for new treatment options 
All available agents for the treatment of osteoporosis have side effects. PTH, for 
example, is approved for osteoporosis treatment for a maximal period of 2 years, 
due to the development of osteosarcomas in rat studies (MCGREEVY & 
WILLIAMS, 2011). As the only bone anabolic agent for osteoporosis treatment 
currently is PTH, and there is still need for novel agents for the treatment of 
osteoporosis, researchers are focusing on new agents that act through biological 
pathways with great potential for developing new therapy strategies. For example 
the Wnt-pathway (CANALIS, 2013), as it has been discovered that an activation of 
this pathway leads to an increase of bone mass (WESTENDORF et al., 2004). The 
EGFR-system may be another potential candidate for the development of new 
therapeutic agents, as its influence on bone homeostasis is quite obvious. Areg is a 
II. Review of the literature     11 
target gene of the anabolic action of PTH, but how this effect is mediated is still 
unclear.  It might be worth to investigate how AREG influences bone formation. 
Uncovering the mechanism by which AREG functions on bone formation may lead 
to the discovery of novel anabolic agents, which could be of use in osteoporosis 
treatment. 
2. Transcriptome studies 
2.1. Transgenic mice as model for gene expression analysis 
Transgenic animals have been used for decades as suitable models for studying 
gene functions, interactions of gene products in biological processes or their role in 
pathological processes (CHO et al., 2009). The method for generating transgenic 
animals by microinjection of foreign DNA into the pronucleus of fertilized mouse 
oocytes, which has first been reported more than 30 years ago (GORDON et al., 
1980), has become a standard and indispensable tool for scientific research since 
and can be found in several overviews (CONNER, 2004; CHO et al., 2009; 
HARUYAMA et al., 2009). Transgenic mouse lines may also be generated with the 
aim of conducting a transcriptome analysis, which may provide more information 
about the mechanism behind the observed phenotypes. 
2.2. Microarray technology 
The successful sequencing of the genome of many organisms was the first step on 
the way before it became possible to examine differences in expression patterns of 
genes. Yet, uncovering the sequences of the genome of an organism alone does not 
yield information about expression patterns or the functions of single genes.  The 
transcribed mRNA is the first step from DNA to protein synthesis. So the transcript 
of an organism is the imprint of the “currently active” genes, which is, unlike the 
genome, very dynamic and changes rapidly with outer stimulation or during 
biological processes (LOCKHART & WINZELER, 2000). The principle behind 
the microarray technology, a powerful tool for transcriptome analysis, is the same 
like Northern or Southern blotting: the target sequences are detected by 
hybridization to a compatible immobilized sequence. An array comprises 
complementary DNA, obtained by PCR from cDNA libraries, immobilized in high 
density on a matrix, usually on glass, at defined positions (termed as probe). The 
mRNA, the transcript of a given cell line or tissue, will then be used to generate a 
fluorescent labeled “target”, that, in turn, will be hybridized to the compatible 
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immobilized sequence (SCHENA et al., 1995; SCHULZE & DOWNWARD, 
2001). The intensity of bound “target”, measured by the fluorescent intensity, 
corresponds to the amount of mRNA isolated from the sample. Because of the high 
density assembly of cDNA on an array, one chip contains many thousands of 
different cDNA clones, and is therefore an appropriate tool for gene expression 
monitoring (LOCKHART & WINZELER, 2000).  
 
 
Figure 3: Microarray analysis scheme 
 
For this work, the Agilent SurePrint Mouse GE 8x60K Microarray Kit (Agilent, 
Waldbronn) was used.  According to the manufacturer, this array comprises ~ 
39500 Entrez gene RNAs and ~ 16000 link RNAs, and covers all currently known 
genes and intergenic, non-coding RNAs 
(HTTP://WWW.GENOMICS.AGILENT.COM/EN/HOME.JSP).  
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2.3. Col1(I)-AREG mouse line for gene expression analysis 
As the specific pathways responsible for AREG effects on osteoblasts are unknown, 
we conducted a transcriptome analysis via microarray to identify the genes up- or 
down-regulated in osteoblasts of Col1(I)-AREG transgenic mice, a mouse line 
overexpressing AREG specifically in osteoblasts (described below), compared to 
wild-type controls. 
For this work, bones, in this case, whole femurs, were used for the microarray 
experiment. We chose different age groups to evaluate possible age-related 
dynamics of the transgene compared to wild-types: 
1 week (newborn) 
4 weeks (adolescent) 
8 weeks (adult) 
As sex steroids are also known to influence bone metabolism (RIGGS et al., 2002), 
we chose only male mice for the experiments. 
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III. MATERIALS AND METHODS 
1. Animals 
1.1. Colα1(I)-AREG transgenic mice 
To examine the potential of AREG to increase bone mass in vivo, a mouse line 
overexpressing AREG specifically in the bone was created in the Gene Center by 
PD Dr. Marlon Schneider. In this mouse line the Areg cDNA is driven by the 
osteoblast-specific murine 2.3 kb collagen α1(I) promoter (DACQUIN et al., 2002) 
to ensure an overexpression only in osteoblasts. 
1.1.1. Generation of mouse line 
Initially, the Areg cDNA (~ 800 bp) was obtained from a mouse skin cDNA library 
by RT-PCR (Platinum Taq DNA Polymerase High Fidelity System (Invitrogen, 
Carlsbad) using the following primers: 
Areg Xba#1:  5` -TAG TCT AGA TTG CTG CAG AGA CCG AGA C- 3` 
 (XbaI sequence underlined) 
Areg Pac#2:  5` -TAG TTA ATT AAG GCA ATG ATT CAA CTT TTA CC- 3` 
(PacI sequence underlined) 
The transcript was cloned into the pCRII-TOPO vector and sequenced to confirm 
amplification fidelity. 
The AREG transcript was excised with the restriction enzymes XbaI and PacI. 
Simultaneously, a 2.3 kb fragment of the mouse α1(I)-collagen promoter was 
excised with a XhoI/XbaI double digest from the pJ251 plasmid, a generous gift 
from G. Karsenty (DACQUIN et al., 2002). The two fragments were then cloned in 
a single step into a XhoI/PacI – opened Bluescript plasmid, containing a bovine 
growth hormone polyadenylation signal. The correct assembly was confirmed by 
multiple restriction enzyme digests and sequencing before the 3.5 kb Col1α(I)-
AREG transgene was released from the Bluescript plasmid backbone by a NotI 
digest. Purification of the transcript DNA was performed by an agarose-gel 
purification method (CHO et al., 2009). 
Zygotes for microinjection were obtained from FVB females, which had been 
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superovulated with PMSG (Intergonan®, Intervet, Unterschleißheim) followed by 
application of HCG (Ovogest®, Intervet, Unterschleißheim) two days later. After 
injection of HCG, donors were mated with male FVB mice. The next day females 
were checked for positive vaginal plugs, the positive ones were killed to collect 
zygotes for DNA microinjection. The method for DNA microinjection into the male 
pronucleus was conducted according to standard methods (CONNER, 2004; CHO 
et al., 2009; HARUYAMA et al., 2009; LIU et al., 2013). The injected zygotes were 
implanted surgically into NMRI foster mothers, which had been plug positive the 
same day as the donors. Born pups were genotyped as described below to identify 
transgenic founders. A total of three positive founders were obtained. Only the lines 
descending from animal 1 (line1, L1) and animal 3 (line3, L3) were positive for the 
transgene. Descendants from animal 2 did not carry the transgene. 
1.1.2. Maintenance of mice 
Mice were maintained under specific pathogen-free conditions in a closed barrier 
facility with autoclave, personal and material barrier.  
Maintenance conditions: 
25° Celsius constantly 
Humidity 45 % 
Overpressure (dynamic, depending on barometric pressure) 
Light program: 12 h light cycle, beginning at 7 am, 12 h dark cycle, beginning at 7 
pm 
Mice were held in Macrolon Cages type II long and type III, weaned and separated 
by sex at the age of 4 weeks. At the same time mice were earmarked and tail tips 
were collected for genotyping. 
All mice had ad libitum access to a standard rodent diet (V1534, Ssniff, Soest) and 
water. Additionally, all mice obtained cage enrichment (red houses, cellulose paper, 
running wheels, etc.) to improve maintenance conditions. All procedures were 
carried out in accordance with the German Animal Protection Law. 
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2. Materials 
2.1. Machines 
Bioanalyzer 2100 Agilent, Waldbronn 
Centrifuge (5417R) Eppendorf, Hamburg 
Chyo MJ-3000 (analytical balance) Chyo, Japan 
Homogenizer  Art Miccra, Müllheim 
Mastercycler® ep realplex  
PCR machine 
Eppendorf, Hamburg 
Nanodrop ND-1000 Peqlab Biotechnology, Erlangen 
Thermocycler Biometra®, Göttingen 
Thermomixer Eppendorf, Hamburg 
2.2. Consumables 
Heat-sealing foils for PCR plates Eppendorf, Hamburg 
Histoacryl® liqid skin glue B. Braun, Melsungen 
QualiPCRTube-stripes Kisher Biotech, Steinfurt 
round bottom tubes, 4 ml Carl Roth GmbH, Karlsruhe  
Standard Rodent diet (V1534) Ssniff, Soest 
Safe-lock tubes (1.5 ml) Eppendorf, Hamburg 
96 well real-time PCR plates Eppendorf, Hamburg 
2.3. Chemicals 
Agarose Invitrogen, Karlsruhe 
Chloroform Merck, Darmstadt 
DEPC Sigma, Deisenhofen 
DNAse I (1U/µl) Thermo Scientific, St. Leon-Roth 
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DNA-Rehydration Solution Promega, Mannheim 
dNTPs Thermo Scientific, St. Leon-Roth 
EDTA VWR, Darmstadt 
Ethanol Carl Roth GmbH, Karlsruhe 
Ethidium bromide Carl Roth GmbH, Karlsruhe 
Gene Ruler, 100 bp Thermo Scientific, St. Leon-Roth 
Glacial acetic acid Carl Roth GmbH, Karlsruhe 
HotStar Taq Polymerase Quiagen, Hilden 
Isopropanol VWR, Darmstadt 
Nuclei Lysis Solution Promega, Mannheim 
Protein Precipitation Solution Promega, Mannheim 
Proteinase K (20 mg/mg) Roche, Mannheim 
Random Hexamer Primer Thermo Scientific, St. Leon-Roth 
Reaction Buffer (5x; 10x) Thermo Scientific, St. Leon-Roth 
RevertAid Reverse Transcriptase Thermo Scientific, St. Leon-Roth 
RNAse Promega, Mannheim 
Ribolock RNAse Inhibitor Thermo Scientific, St. Leon-Roth 
SYBR® Green Lonza, Basel 
Tris Carl Roth GmbH, Karlsruhe 
Trizol® Reagent Life technologies, Carlsbad 
2.4. Kits 
Agilent RNA Spike-In Kit, One Color, Cat. 5188-5282, Agilent, Waldbronn 
Agilent Low-Input QuickAmp Labeling Kit, Cat. 5190-2331, Agilent, Waldbronn 
Agilent Cyanine 3 CTP Dye Pack, No. 5188-1169-P, Agilent, Waldbronn 
Agilent Gene Expression Hybridization Kit, Cat. 51885242, Agilent, Waldbronn 
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Agilent Microarray Chip G4852A surePrint Mouse GE 8*60k, Cat. 4852-60510, 
Agilent, Waldbronn 
Platinum Taq DNA Polymerase High Fidelity System, Invitrogen, Carlsbad 
Taq DNA polymerase Kit, Quiagen, Hilden 
Wizard DNA Purification Kit, Promega, Mannheim 
3. Methods 
3.1. Genotyping of mice 
Mice destined for the 4 weeks and 8 weeks groups were marked by ear punches and 
tail tip samples for genotyping were collected before sacrifice. A small piece from 
the end of the tail was cut with a pair of scissors and the wound treated with 
Histoacryl® liquid skin glue (B. Braun, Melsungen). The animals for the 1 week 
group were killed and tail tips for genotyping were collected simultaneously. The 
tail tip samples were immediately frozen on dry ice and stored in a 1.5 ml Eppendorf 
tube at -80° C before further processing. 
3.1.1. DNA-isolation 
Tail tip samples were incubated overnight in 1.5 ml safe-lock tubes (Eppendorf, 
Hamburg) at 56° C, shaking slightly, with 620 µl tissue digestion mix buffer, 
containing: 
500 µl Nuclei Lysis Solution (Promega, Mannheim) 
120 µl 0.5 M EDTA pH 8,0 
17.5 µl Proteinase K, 20 mg/ml, Roche, Mannheim. 
Further processing next day started with adding 3 µl of RNAse (Promega, 
Mannheim) and incubating at 37° C for 20 min, with moderate shaking. 
Next, 200 µl of Protein Precipitation Solution (Promega, Mannheim) were added, 
the tube was vortexed vigorously for 20 s, and then stored on ice for approximately 
5 min. After that, the tubes were centrifuged at 20000 x g. After centrifugation, the 
supernatant, which contained the DNA, was removed carefully without taking the 
protein pellet from the bottom, and transferred into another 1.5 ml safe-lock tube 
containing 600 µl isopropanol (VWR, Darmstadt). The DNA precipitated after 
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inverting the tube gently for several times. Probes were centrifuged again at 20000 
x g to obtain a DNA pellet at the bottom of the tube. Isopropanol was poured of 
carefully and the remaining pellet was washed with 600 µl 70% ethanol (Carl Roth, 
Karlsruhe). After centrifuging the probes again, ethanol was also poured of, small 
remnants were removed by a 10 µl pipette and the pellet was air-dried for 
approximately 10 min. To dissolve the dried pellet, 50 µl of DNA Rehydration 
Solution (Promega, Mannheim) were added and the tubes either incubated for 1 h 
at 65° C or stored overnight at +4° C before further processing. 
3.1.2. PCR 
For PCR the Taq DNA Polymerase Kit, Category 1000 Units (Qiagen, Hilden) and 
QualiPCRTube-strips, RNAse-, DNAse- and pyrogen-free (Kisher Biotech, 
Steinfurt) were used. 
For each probe, a mastermix, containing the following components was prepared: 
10x CoralLoad Reaction Buffer 2 µl 
dNTPs, 1 mM 2 µl 
Q-Solution, 5x 4 µl 
MgCl 2 1.25 µl 
Primer (sense) 1 µl 
Primer (antisense) 1 µl 
Bidistilled water 7.65 µl 
Taq DNA-polymerase 0.1 µl 
DNA-probe 1 µl 
Primers were: 
Areg Xba#1 (sense primer): 
5` TAG TCT AGA TTG CTG CAG AGA CCG AGA C 3` 
 Areg Pac#2 (antisense primer): 
5` TAG TTA ATT AAG GCA ATG ATT CAA CTT TTA CC 3` 
Reaction protocol for thermocycler (Biometra®, Göttingen): 
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1. 94° C – 5 min 
2. 94° C – 1 min 
3. Annealing temperature for above primers: 56° C – 1 min 
4. 72° C – 2 min 
5. 72° C – 10 min 
6. 4° C – till further process 
(Step 2 to 4 were repeated 35 times before proceeding to step 5) 
3.1.3. Gel electrophoresis 
For gel electrophoresis, a 1.5% agarose gel was prepared. To visualize the PCR 
product ethidium bromide (Carl Roth GmbH, Karlsruhe) which intercalates into 
DNA and can be made visible under UV light, was added. The gel was run at 100 
V for approximately 30 to 40 min with a 1xTAE running buffer. 
50xTAE stock contained: 
Tris   242 g 
Glacial acetic acid 57.1 ml 
EDTA pH 8.0, M 0.5 100 ml 
3.2. Sample collection for transcriptome analysis 
Mice were killed by cervical dislocation or, in the case of the 1 week group, 
decapitated with scissors. Originally, a total of 21 animals for both the 1 week (12 
male, 9 female) and the 4 weeks groups (15 male, 6 female) were sacrificed. For 
the 8 weeks group a total of 10 animals (only male) were sacrificed. Both femurs 
were taken out, cleaned of remaining adjacent tissues with a clean cellulose tissue 
and immediately frozen on dry ice to avoid RNA damage. The samples were stored 
at -80° C before further process. For RNA isolation only the right femora were used. 
For each age-group three samples of male animals per genotype were chosen for 
the transcriptome analysis. All experiments were approved by the author’s 
institutional committee on animal care and carried out in accordance with the 
German Animal Welfare Act. 
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3.3. Transcriptome analysis 
3.3.1. RNA isolation 
For the extraction of RNA from the femurs the Trizol® Reagent protocol was 
adopted. 1.7 ml Trizol® were added to the frozen femurs and they were 
immediately homogenized with a Homogenizer (Art Miccra, Müllheim) in a 4 ml 
round bottom tube.  
Phase separation: 
0.8 ml of the mix were transferred to a new reaction tube and 160 µl chloroform 
(0.2 ml chloroform/1 ml Trizol) were added and shaked vigorously per hand for 15 
s. The mixture was then incubated at room temperature for 10 min, followed by 
centrifugation for 35 min, 20000 x g at 4° C. A separation of the mixture was now 
visible: an upper red phenol-chloroform-phase, a cloudy white interphase and a 
lower clear phase.  
Precipitation: 
The upper clear phase, which contains the RNA, was removed with a pipette into a 
new reaction tube and 0.4 ml isopropanol (0.5 ml isopropanol/1 ml Trizol®) were 
added, vortexed and incubated at room temperature for 10 min. Next the tubes were 
centrifuged for 45 min, 20000 x g at 4° C to obtain an RNA pellet at the bottom of 
the tube. 
RNA wash: 
The supernatant was discarded and the RNA washed with 0.8 ml 75% ethanol (1 
ml ethanol/1 ml Trizol®). Next, the tubes were again centrifuged at 25000 x g for 
10 min at 4° C. This step was repeated after discarding the supernatant and washing 
again with 0.4 ml ethanol (0.5 ml ethanol/1 ml Trizol®). 
After taking of the supernatant ethanol, the tubes were centrifuged shortly and the 
remaining ethanol was taken with a pipette. The RNA pellet was dried carefully at 
the flame of a Bunsen burner for approximately 6 min, till it became clear. 
RNA resuspension 
70 µl of RNAase-free water was added to the tubes for resuspension and an 
incubation step followed for 20 min at 35° C on a thermomixer. 
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Quality of RNA 
Quality and concentration of RNA were assessed by Nanodropspectrophotometer 
and Bioanalyzer. Additionally an agarose gel was run for quality control of RNA. 
A 260:280 ratio of ~2 is considered “pure” for RNA (Nanodrop). Quality control 
with Bioanalyzer: RNA integrity number (RIN) was for all samples 8.5 – 10 (10: 
very good quality of RNA; 1: very poor quality/contaminated RNA) 
3.3.2. Microarray analysis 
The microarray experiments were kindly conducted by members of the laboratory 
of Dr. Helmut Blum in the Gene Center. 
Before hybridization with the Agilent Microarray Chip (Agilent Gene Expression 
Hybridization Kit, Agilent, Waldbronn) fluorescent cRNA synthesis with Cyanine3 
was conducted with the QuickAmp Labeling Kit, one color (Agilent, Waldbronn) 
according to the manufacturer’s instructions. 
Figure 4 shows a diagram with the steps for Microarray chip hybridization. 
 
 
Figure 4: Hybridization process of probe with microarray chip 
Modified from Agilent user’s manual for One-Color Microarray-Based Gene 
Expression Analysis 
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3.3.3. Statistical and bioinformatical analysis of raw microarray data 
The statistical and bioinformatical analysis of the raw Agilent Array data was 
kindly conducted by Alexander Graf of the laboratory of Dr. Helmut Blum in the 
Gene Center, Munich. 
3.3.4. Evaluation of array data with GO-analysis 
The obtained lists of differentially expressed genes were further analyzed with the 
free online bioinformatics resource DAVID (Database for Annotation, 
Visualization, and Integrated Discovery) (Version: 6.7) (DENNIS et al., 2003) and 
the open source bioinformatics network Cytoscape (Version: 3.0.2) (SHANNON et 
al., 2003). These tools were used to search for overrepresented annotation 
categories and visualize correlations between the found terms and the selected 
genes. For the analysis with Cytoscape, the basic settings of the program with the 
Apps CluGo and CluPedia were used, except for the analysis of the down-regulated 
genes of the 1 week group. Network specificity was positioned halfway between 
“medium” and “significant” for this gene list, as the basic setting (positioned near 
“medium”) yielded no manageable result. 
As the overexpressed Areg-gene was inserted artificially, it was excluded from the 
analyzed lists of differentially expressed genes for all age-groups. 
3.4. Quantitative RT-PCR 
3.4.1. cDNA synthesis 
Three samples of the 1 week group and three of the controls were chosen for cDNA 
synthesis and quantitative RT-PCR. A final amount of 1 µg of RNA was used for 
cDNA synthesis.  
DNAse digest 
1 µl of 10x Reaction buffer and 1 µl of DNAse I (1U/µl) (Thermo Scientific, St. 
Leon-Roth) were added to each sample in safe lock tubes and incubated for 30 min 
at 37° C in a thermomixer. After incubation 1 µl of 50 mM EDTA was added to 
each sample to stop the enzymatic reaction. Another incubation step at 65° C for 10 
min followed.  
Reverse transcription 
First 1 µl of Random Hexamer Primer (Thermo Scientific, St. Leon-Roth) was 
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pipetted to each sample and an incubation step at 65° C for 5 min followed. 
For reverse transcription to each sample was added: 
4 µl  5x Reaction Buffer (Thermo Scientific, St. Leon-Roth) 
0.5 µl Ribolock RNAse Inhibitor (Thermo Scientific, St. Leon-Roth) 
2 µl  dNTPs 10 mM (Thermo Scientific, St. Leon-Roth) 
1 µl RevertAid Reverse Transcriptase (Thermo Scientific, St. Leon-Roth) 
Three incubation steps followed: 
Step 1 25° C for 10min 
Step 2 42° C for 1 hour 
Step 3 70° c for 10min 
Before storage at -80° C, cDNA presence was checked by PCR with a housekeeping 
gene (Gapdh). 
3.4.2. qRT-PCR 
The qRT-PCR was kindly conducted in the laboratory of Prof. Dr. Frank Kolligs 
by Andrea Ofner.  
For the qRT-PCR 96 well real-time PCR plates (Eppendorf, Hamburg), a heat 
sealing foil (Eppendorf, Hamburg), the intercalating fluorescent dye SYBR® Green 
(Lonza, Basel), the Taq DNA polymerase Kit and HotStar Taq polymerase 
(Quiagen, Hilden) were used. Total reaction volume was 20 µl. Reactions were run 
in a Mastercycler® ep realplex PCR machine (Eppendorf, Hamburg), with the 
following protocol: 
Step 1:  95° C, 15 min (DNA denaturation) 
Step 2:  95° C, 30 s (DNA denaturation) 
Step 3:  55 °C, 30 s (primer annealing) 
Step 4:  72° C, 30 s (elongation) 
Step 5:  82° C, 20 s (DNA quantification) 
Step 6:  95° C, 15 s (DNA denaturation) 
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Step 7:  95° C, 15 s 
Step 8: continuously increasing heat to 95° C, 20 min (melting 
curve determination) 
Step 9: 95° C, 15 s 
Steps 2 to 5 were repeated 55 times. 
qRT-PCR data was analyzed with the deltaCT method as described 
(SCHMITTGEN & LIVAK, 2008). 
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IV. RESULTS 
1. Results of transgenic mice generation 
1.1. Confirmation of bone-specific overexpression of AREG and 
increased bone mass in Col1(I)-AREG mice 
Bone specific overexpression of AREG in Col1(I)-AREG – transgenic mice was 
confirmed by Northern blot analysis for both L1 and L3 animals (unpublished data, 
not shown). The initial phenotypic characterization of this new mouse line also 
included the examination of the bones of transgenic animals and wild-type 
littermates by µCT and peripheral quantitative computed tomography (pQCT) as 
described previously (SCHNEIDER et al., 2012). 
 
 
Figure 5: µCT analysis of distal femur 
Kindly provided by PD Dr. Marlon Schneider. 
A: 3D image of distal femur of control and transgenic L1 mice; data for image 
obtained from µCT analysis; 
B: total bone mass density by µCT analysis for L1 animals; 
C: total bone mass density by µCT analysis for L3 animals; 
 
These measurements showed an increase in trabecular and total bone mineral 
density in the distal femur (µCT) (Figure 5) and a significant increase in total bone 
mineral density in the distal femur (pQCT). The effect could be observed both in 
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L1 and L3 animals, so these results confirmed an AREG-induced anabolic effect 
on bones of the transgenic Col1(I)-AREG mouse-lines. Data shown in Figure 5 
were from 8 weeks old mice. Additionally, unpublished studies also revealed a 
decreased number of osteoclasts of Col1(I)-AREG mice (data not shown), which 
had been taken into special account for the analysis of the gene expression results. 
All the observed effects in Col1(I)-AREG mice were strongest in young age and 
completely disappeared with older age (unpublished data). 
Figure 6 shows an example of a RT-PCR analysis for demonstrating expression of 
the transgene-derived Areg. As the primers for the Col1(I)-AREG transgenic mouse 
line are designed for the cDNA, there is no visible band in the wild-type mouse. 
Therefore, a loading control with a house keeping gene was necessary. 
 
 
Figure 6: Example for PCR analysis 
A: PCR analysis of Col1(I)-AREG transgenic and wild-type littermates; upstream 
primer located in exon 1, downstream primer located in exon 6 of the amphiregulin 
sequence, resulting in a 847 bp fragment for transgenic mice. 
B: example for loading control (Erbb2); upstream and downstream primers both 
located in Intron 10 resulting in a 218 bp long fragment  
for primer sequences see addendum IX.3.1 
IV. Results     28 
1.2. Killing of mice and bone collection 
For the gene expression analysis, mice were killed at day 10 after birth for all 
animals of the 1 week group, at day 31 for the 4 weeks group and at day 57 after 
birth for the 8 weeks group. Mice were killed by cervical dislocation, or in the case 
of the 1 week group, beheaded by scissors. Both femurs were removed from the 
carcass, cleaned of remaining tissues with a paper towel, and immediately frozen 
on dry ice. There were no visible differences between the transgenic and the wild-
type animals. The right femur of each animal was used for RNA isolation. 
1.3. Body weight 
All mice were weighed before necropsy. With the exception of the 8 weeks group, 
there were no significant differences in body weight between the transgenic and the 
wild-type animals (Table 1). In the 8 weeks group, wild-type animals were heavier 
than the transgenic mice. 
 
Table 1: Weighs of mice at the different ages. 
Weighs of wild-type and transgenic animals were compared by Student`s t-test.  
p < 0.05 was considered significant. 
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2. Microarray analysis 
2.1. RNA quality analysis 
RNA was isolated with TrizolReagent (Life Technologies, Carlsbad) according to 
the manufacturer’s instructions. The isolated RNA will be used to produce the 
labeled target, which, in turn, will be used to hybridize with the array. Therefore, 
RNA with a very high purity and integrity is essential to achieve reliable results.  
To evaluate RNA quality and purity before processing to the microarray 
hybridization, Nanodrop measurement and gel electrophoresis were done.  
The Nanodrop measurement yielded a ratio 260:280 in the range of 1.7 – 2.0 and a 
ratio 260:230 in the range of 2.1 – 2.5, indicating pure RNA, as contaminants like 
proteins, salts or others would be absorbing light at 230 nm or 280 nm. 
 
Table 2: Results of Nanodrop measurement 
 
 
Additionally, RNA integrity was analyzed, as purity does not indicate whether RNA 
is intact or not. To visualize intact RNA strands, a 1% agarose gel was prepared for 
gel electrophoresis. Two clear bands were visible, representing the 18S and 28S 
ribosomal RNA, indicating intact RNA (Figure 7). A ratio 28S:18S of 2 is typical 
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for intact RNA. An analysis on agarose gel was done additionally for quality control 
to exclude a possible contamination with genomic DNA which would not have been 
detected by the Bioanalyzer. The area of possible contamination with genomic 
DNA is marked on the image section (Figure 7). 
 
Figure 7: RNA quality analysis on agarose gel  
 
Integrity of RNA used for the microarray was furthermore confirmed with the 
Bioanalyzer (Agilent 2100 Bioanalyzer, Agilent, Waldbronn), a microfluidic 
instrument, that is more sensitive and able to analyze smaller amounts of RNA. 
Data can be visualized as a gel-like image or an electrospherogram. Figure 8 shows 
the gel-like image of the analysis with the Bioanalyzer. 
 
 
Figure 8: Gel-like image of RNA-analysis with Bioanalyzer 
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The Bioanalyzer evaluates RNA integrity by RIN (RNA integrity number), a 
standardized tool for RNA quality assessment. A RIN of 1 stands for the highest 
degradation grade, 10 for best quality. All samples ranked from RIN 8.5 – 10 
(Figure 9). 
 
 
Figure 9: Example for RIN-quality analysis with the Bioanalyzer 
 
2.2. Statistical and bioinformatical analysis of the array data 
After hybridization, the slides were scanned with an Agilent DNA Microarray 
Scanner (G2505C, Agilent, Waldbronn), and image processing was performed with 
Feature Extraction Software 10.5.1.1. (Agilent, Waldbronn). Probes were first 
filtered for those which are above background noise before data normalization with 
VSN, version 3.18.0 (HUBER et al., 2002). Quality control of the normalized data 
was conducted with an Euclidian distance matrix. The output data is a heat map, 
which shows high similarity of the data coded in red or otherwise lowest similarity 
coded in dark blue.  
Figure 10 shows the resulting heat maps of this quality control. Additionally to the 
color code, the branches of the cluster trees indicate the clustering of genes. For the 
1 week and the 4 weeks groups (Figure 10, A and B), wild-types were clustering 
together, as were the transgenic animals. For the 8 weeks group, two animals had 
to be excluded, because of aberration. But the branches of the cluster tree indicate 
that, nevertheless, no satisfactory clustering for each wild-types and transgenics 
could be achieved (Figure 10, C). 
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Figure 10: Heatmaps 
A: Heatmap of 1 week group 
B: Heatmap of 4 weeks group 
C: Heatmap of 8 weeks group 
 
Significance analysis to detect differentially expressed genes was done with 
Limma, version 3.6.9. Genes with a two-fold difference in expression (Log2 Fold 
change ≥ 1 for upregulated genes; Log2 Fold change ≤ 1 for downregulated genes) 
with an adjusted p-value < 0.05 were considered significant. To further analyze the 
obtained genes, a SOTA (self-organizing-tree-algorithm) - analysis was conducted. 
The principle behind this analysis is to cluster differentially expressed genes with a 
similar expression pattern (HERRERO et al., 2001). For each age-group, two 
clusters of genes were grouped (Figure 11). The highest amount of clustering genes 
could be detected in the 1 week group (184 down-regulated genes, 47 up-regulated 
genes), with a distinct drop in the number of clustering genes in the 4 weeks group 
(8 down-regulated genes, 56 up-regulated genes) and no differentially expressed 
IV. Results     33 
genes clustering together in the 8 weeks group. 
 
 
Figure 11: Sota-cluster analysis 
A: Cluster-analysis for 1 week age-group; 184 down-regulated (left) and 47 up-
regulated (right) genes for transgenic animals compared to wild-type control 
B: Cluster-analysis for 4 weeks age-group; 56 up-regulated (left) and 8 down-
regulated (right) genes for transgenic animals compared to wild-type control 
C: Cluster-analysis for 8 weeks age-group; 462 and 450 genes clustering; no 
distinct up- or down-regulation 
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Figure 11 shows that the number of differentially regulated genes that could be 
found decreased with age. In the 8 weeks group the array results showed no 
difference between the transgenic compared to the wild-type group. So the most 
significant effect was observed in the youngest group. This effect might be 
indicating that other genes are possibly compensating the effect of bone-specific 
AREG overexpression. 
2.2.1. GO Analysis 
Transcriptome analyses yield results up to thousands of genes, which makes it 
impossible to analyze the dataset gene by gene. Appropriate tools have been 
developed to enable not only the analysis of single genes but a functional annotation 
of huge datasets. They are based on the standardized “gene vocabulary” developed 
by the Gene Ontology Consortium (ASHBURNER et al., 2000) comprising the 
three categories biological process, molecular function and cellular component. A 
given set of genes can be analyzed with these tools to search for enriched terms, to 
get a general idea of the connection of those genes.  
For this work, a tool provided by the free online bioinformatics resource DAVID 
(Database for Annotation, Visualization, and Integrated Discovery) (Version: 6.7) 
(DENNIS et al., 2003) was used to search for enriched GO-terms in the categories 
mentioned above: the Functional Annotation Clustering Tool.  This tool is able to 
measure the “relationship” of annotated terms from different sources and groups 
them together in annotation groups, thus reducing redundant terms and enabling to 
visualize directly overrepresented categories without searching through long lists 
of annotation terms. Additionally, the open source bioinformatics network 
Cytoscape (Version: 3.0.2) was used. Cytoscape (SHANNON et al., 2003) was used 
with the plug-ins CluGo (Version: 2.0.7) (BINDEA et al., 2009) and CluPedia 
(Version: 1.0.8) (BINDEA et al., 2013) to create a network graph, with nodes and 
edges as links, thus visualizing correlation between the found terms and the genes 
selected by Cytoscape for the enriched terms. CluGo integrates not only GoTerms 
(ASHBURNER et al., 2000), but also KEGG/BioCarta pathways (KANEHISA, 
2002) to create a functionally organized GO/pathway term network; it enables to 
analyze a single list of genes or to compare different lists of genes and to visualize 
their functional differences/relationships in a color coded network graph (BINDEA 
et al., 2009).  
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2.2.2. Differentially expressed genes of the 1 week group 
The lists of differentially expressed genes for this group can be found in IX.4.1 and 
IX.4.2. 47 up-regulated and 184 down-regulated differentially expressed genes 
could be found for the 1 week group. 
Functional annotation clustering analysis of the obtained lists of differentially 
expressed genes was conducted using the free web-based database DAVID.  
 
Table 3: DAVID – selected Functional Annotation Cluster-results for 1 week 
group, up-regulated genes 
(Numbers in brackets are number of genes and fold enrichment of the functional 
term; 
Enrichment score is geometric mean of member’s p-values of corresponding 
annotation cluster (in –log scale)) 
 
 
The analysis of the differentially expressed up-regulated genes yielded GO-terms 
for biological processes in the extracellular region, EGF-like domain, nervous 
system development and apoptosis (see Table 3). Table 4 lists the genes sorted by 
DAVID to the annotation terms of Table 3. 
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Table 4: Gene List to Annotation terms for 1 week group, up-regulated genes 
 
 
The analysis of the up-regulated genes with the program Cytoscape yielded results 
in the form of a diagram visualizing the connections between the genes and the 
biological processes as nodes and edges (Figure 12), the same analysis also being 
presented as table (see Table 5).  Figure 12 and Table 5 show clearly that there are 
2 genes, Dcstamp and Spp1, overrepresented in biological processes regarding bone 
metabolism.  
Spp1 (also known as Osteopontin, OPN) is one of the genes overrepresented in both 
analyses. DAVID and Cytoscape also revealed genes like for example Enpp1, Slit2, 
Map1b (or also known as Mtap1b) and Cdkn2a (also known as p16) in annotation 
terms regarding growth in general. 
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Figure 12: Cytoscape diagram of 1 week group, up-regulated genes 
 
Table 5: Genes corresponding to biological processes for 1 week group, up-
regulated genes 
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sprouting angiogenesis 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0
cell migration involved in sprouting angiogenesis 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0
motor axon guidance 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0
positive regulation of cell-substrate adhesion 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0
microtubule-based transport 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1
muscle cell migration 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0
smooth muscle cell migration 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0
olfactory bulb development 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0
olfactory lobe development 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0
negative regulation of cell growth 1 0 1 0 0 1 0 0 0 1 1 0 0 0 0
neutrophil chemotaxis 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0
cytoskeleton-dependent intracellular transport 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1
mammary gland epithelial cell proliferation 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
regulation of mammary gland epithelial cell proliferation 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
negative regulation of mammary gland epithelial cell proliferation 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
regulation of tissue remodeling 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0
positive regulation of tissue remodeling 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0
blood vessel endothelial cell migration 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0
regulation of bone resorption 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0
bone resorption 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0
positive regulation of bone resorption 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0
bone remodeling 0 0 1 0 0 1 0 0 0 0 1 0 0 0 0
regulation of bone remodeling 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0
positive regulation of bone remodeling 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0
developmental cell growth 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0
negative regulation of epithelial cell proliferation 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
mammary gland morphogenesis 1 0 0 0 0 0 1 0 0 1 0 0 1 0 0
mammary gland duct morphogenesis 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0
mammary gland epithelium development 1 0 0 0 0 0 1 0 0 1 0 0 0 0 0
regulation of extent of cell growth 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0
negative regulation of proteolysis 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0
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For the differentially expressed down-regulated genes, DAVID found GO-terms in 
the categories hematopoiesis and immune system development, amino acid 
transport and cytoskeleton organization (Table 6). The differentially expressed 
genes belonging to the annotation terms of Table 6 are listed in Table 7. 
 
Table 6: DAVID – selected Functional Annotation Cluster-results for 1 week 
group, down-regulated genes 
(Numbers in brackets are number of genes and fold enrichment of the functional 
term; 
Enrichment score is geometric mean of member’s P values of corresponding 
annotation cluster (in –log scale)) 
 
Table 7: Gene List to Annotation terms for 1 week group, down-regulated 
genes 
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The differentially down-regulated genes were also analyzed with Cytoscape. For 
the diagram see Figure 13.  
Table 8 shows the genes from the diagram attributed to the biological processes. 
The Cytoscape analysis yielded results similar to those obtained with DAVID 
(Table 7); overrepresented terms were biological processes associated with 
hematopoiesis, genes found by both programs for several annotation terms were for 
example Alas2, Fech, Tal1. Genes associated with bone metabolism were not 
detected.  
 
 
Figure 13: Cytoscape diagram of 1 week group, down-regulated genes 
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Table 8: Genes corresponding to biological processes for 1 week group, 
down-regulated genes 
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transition metal ion transport 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 1 0 0
neurotransmitter uptake 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
myeloid leukocyte differentiation 0 1 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0
regulation of myeloid leukocyte differentiation 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
catecholamine metabolic process 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
glutathione metabolic process 0 0 0 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
protoporphyrinogen IX biosynthetic process 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1
heme biosynthetic process 0 0 1 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1
iron ion transport 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0
amino acid transport 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 0
cellular iron ion homeostasis 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
catechol-containing compound biosynthetic process 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
neutral amino acid transport 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0
myeloid cell differentiation 0 1 1 0 0 1 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 1 1 1 1 0
erythrocyte differentiation 0 0 1 0 0 1 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 1 0
megakaryocyte differentiation 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
platelet formation 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
basophil differentiation 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
granulocyte differentiation 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
negative regulation of histone modification 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
microtubule polymerization or depolymerization 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0
iron ion transmembrane transport 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0
embryonic hemopoiesis 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0
dopamine biosynthetic process 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
dopamine metabolic process 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
catecholamine biosynthetic process 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
erythrocyte maturation 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0
regulation of erythrocyte differentiation 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
astrocyte differentiation 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0
erythrocyte development 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0
positive regulation of synaptic transmission 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
response to cortisol stimulus 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
regulation of neurotransmitter uptake 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
iron ion homeostasis 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0
definitive hemopoiesis 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
long-term synaptic potentiation 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
cellular response to corticosteroid stimulus 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cellular response to glucocorticoid stimulus 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
response to dexamethasone stimulus 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cellular response to dexamethasone stimulus 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
negative regulation of chromosome organization 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
positive regulation of chromosome organization 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
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2.2.3.  Differentially expressed genes of the 4 weeks group 
56 differentially up-regulated genes and 8 down-regulated genes could be identified 
for this group (IX.4.3 and IX.4.4). 
DAVID yielded a functional annotation clustering report only for the up-regulated 
genes (Table 9). Found GO-terms were mainly extracellular region and embryonic 
limb morphogenesis. 
 
Table 9: DAVID – selected Functional Annotation Cluster-results for 4 weeks 
group, up-regulated genes 
(Numbers in brackets are number of genes and fold enrichment of the functional 
term; 
Enrichment score is geometric mean of member’s P values of corresponding 
annotation cluster (in –log scale)) 
 
 
Table 10: Gene List to Annotation terms for 4 weeks group, up-regulated 
genes 
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The Cytoscape analysis yielded similar results, with terms for biological processes 
regarding growth, proliferation and differentiation of cells in general. 
Overrepresented genes found by both programs were again Spp1 and Slit2, along 
with Prrx1 and Prrx2 (Figure 14 and Table 11).  
The small number of the down-regulated genes did not yield any annotation results 
by both DAVID and Cytoscape. 
 
 
Figure 14: Cytoscape diagram of 4 weeks group, up-regulated genes 
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Table 11: Genes corresponding to biological processes for 4 weeks group, up-
regulated genes 
 
 
2.2.4. Differentially expressed genes of the 8 weeks group 
In this age-group, no differentially expressed genes were revealed by the microarray 
analysis, except for Areg, which could still be detected by microarray with a 24.2-
fold up-regulation. 
2.3. qRT-PCR results 
qRT-PCR was conducted to verify a small selection of genes (Dcstamp and Mmp9) 
identified by the microarray analysis and to examine two other genes known to 
influence osteoclast differentiation (Rankl and Opg) which had not been detected 
by microarray analysis. Gapdh was employed as a house keeping gene. The qRT-
PCR was only done for the 1 week group. The sequences of the primers can be 
found in IX.3.2. 
As Figure 15 shows, the results differ from the ones of the microarray analysis. 
None of the examined genes was significantly regulated. While the analysis via 
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positive regulation of endothelial cell proliferation 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0
regulation of cytokine-mediated signaling pathway 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0
negative regulation of cytokine-mediated signaling pathway 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0
sprouting angiogenesis 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0
cell migration involved in sprouting angiogenesis 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0
positive regulation of mesenchymal cell proliferation 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0
motor axon guidance 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0
regulation of smoothened signaling pathway 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0
regulation of mesenchymal cell proliferation 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0
positive regulation of cell-substrate adhesion 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0
microtubule-based transport 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1
muscle cell migration 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 0
smooth muscle cell migration 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 0
regulation of smooth muscle cell migration 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0
negative regulation of ossification 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0
neutrophil chemotaxis 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0
cytoskeleton-dependent intracellular transport 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1
neuron projection regeneration 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0
axon regeneration 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0
regulation of tissue remodeling 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
positive regulation of tissue remodeling 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
middle ear morphogenesis 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0
blood vessel endothelial cell migration 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0
negative regulation of proteolysis 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0
positive regulation of smoothened signaling pathway 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0
platelet-derived growth factor receptor signaling pathway 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0
developmental cell growth 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0
embryonic cranial skeleton morphogenesis 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0
artery morphogenesis 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0
regulation of response to cytokine stimulus 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0
negative regulation of response to cytokine stimulus 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0
artery development 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0
regulation of extent of cell growth 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0
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microarray indicated that the levels of Mmp9 and Dcstamp of the transgenic animals 
were increased compared to the wild-type control, the qRT-PCR analysis did not 
confirm this result. For Rankl and Opg, which had not been detected by microarray 
analysis, no significant up-or down-regulation was detected by qRT-PCR either.  
 
 
Figure 15: Results of qRT-PCR  
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V. DISCUSSION 
Amphiregulin has been identified as a possible PTH-target gene, and might be one 
of the factors influencing the anabolic actions of PTH on bone formation via the 
EGFR. The aim of this work was to search for genes up- or down-regulated in the 
bones of transgenic mice overexpressing Areg, which show an increase in bone 
mass.   
1.1. Col1(I)-AREG mouse line for transcriptome analysis 
A transgenic mouse line, the Col1(I)-AREG mouse line, had been generated to 
obtain osteoblast-specific Areg overexpression. Transgenic animals are excellent 
models for studying precise functions of single genes and their interactions in 
biological processes (CHO et al., 2009). Since the first generation of transgenic 
animals in 1980 (GORDON et al., 1980), there has been great improvement in the 
techniques, yet sometimes the transgene is not working as it is expected to be. It 
has been described, for example, that a transgene inserted as cDNA rather than 
genomic DNA may show a poorer performance (HOUDEBINE, 2002), or that the 
chromosomal sequences flanking the transgene have a great influence on enhancing 
or repressing the transgene (CRANSTON et al., 2001). The Col1(I)-AREG mouse 
line had been constructed with a cDNA insertion, but the transgene seems to be 
working, as overexpression of AREG was detected and a bone anabolic effect could 
be observed in two independent transgenic mouse lines. This makes the Col1(I)-
AREG mouse line a suitable model for this work. 
1.2. Weight and phenotype of transgenic animals 
In the 8 weeks group, wild-type mice were found to be heavier. For the other age-
groups no significant difference in the weight of the animals could be detected.  The 
µCT and pQCT examinations of the femur revealed differences in the bone 
phenotype between the transgenic and the wild-type mice. These examinations 
confirmed a specific bone phenotype for this mouse line, which was age-dependent. 
All the observed effects diminished with higher age (mice aged 5 months and older 
did not show any differences in the bone phenotype – unpublished data). This might 
also be an explanation for the higher weight of wild-type animals in the 8 weeks 
group. As the phenotype is not stable over time, the lower weight of the transgenic 
animals might simply be due to a transient, so far unidentified effect for this mouse 
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line. 
1.3. Transcriptome analysis  
We conducted a transcriptome analysis via microarrays to identify genes potentially 
involved in the high bone mass phenotype of Col1(I)-AREG mice. A GO analysis 
using the free online bioinformatics resource DAVID and the open source 
bioinformatics network Cytoscape was conducted with the obtained lists of 
differentially expressed genes to identify regulated genes which had been sorted 
into overrepresented annotation categories by these tools. Genes of interest were 
preferably such with an already known influence on osteoblast proliferation, and, 
as unpublished examinations of this transgenic mouse line also hinted to a decrease 
in osteoclast number, genes involved in osteoclast proliferation and differentiation. 
This analysis yielded results for overrepresented annotation terms mainly for 
biological processes concerning growth, proliferation and cell migration for the up-
regulated genes of the 1 week and 4 weeks groups. A GO-analysis for the down-
regulated genes could only be conducted for the 1 week group as the list for the 4 
weeks group contained only 8 differentially expressed genes. No GO-analysis could 
be conducted for the 8 weeks group, as no differentially expressed genes were found 
by the microarray analysis. Additionally, the microarray analysis confirmed Areg 
overexpression for all age groups, as it could be detected in all age groups as up-
regulated, although the up-regulation of Areg itself and the effect of it on other 
genes seems to be age-dependent, as in the 8 weeks group no difference of other 
differentially expressed genes between the transgenic and wild-type animals could 
be detected. Thus, there might be some certain compensatory effect of other genes 
in older ages. AREG is expressed in nearly all tissues of the body, and is 
physiologically involved in biological processes like growth, tissue repair, cell 
migration and apoptosis (BERASAIN & AVILA, 2014). The most distinct role that 
could be identified for AREG is its importance for mammary gland development, 
especially for mammary gland duct branching (LUETTEKE et al., 1999). This 
function was actually highlighted by the Cytoscape analysis for the 1 week group. 
Another important function of AREG has been reported in inflammation and 
regeneration of the liver (PARDO-SAGANTA et al., 2009). It has also been shown 
that mice lacking Areg had significantly less trabecular bone in the tibia with no 
differences in the midshaft of the femur (LUETTEKE et al., 1999; QIN et al., 2005). 
This might be because the influence of AREG on bone metabolism does not extend 
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to all bone compartments. A possible explanation for this effect might be the fact 
that AREG acts through specific EGFR homo- or heterodimers (compared to other 
EGFR-ligands), thus initiating specific intracellular signaling cascades 
(SCHNEIDER & WOLF, 2009).  
As the GO-analysis of the differentially expressed genes with DAVID and 
Cytoscape yielded quite manageable lists of genes, some of them could be assessed 
individually. Some of the most prominent are discussed below, the up-regulated 
genes first. The majority of these up-regulated genes actually have an already 
known function in bone homeostasis. 
SPP1 (Secreted Phosphoprotein 1), also called OPN (Osteopontin), is a 
phosphoprotein secreted by many cells of various tissues. In bone it is expressed by 
osteoblasts at various stages of differentiation and also by osteoclasts (SODEK et 
al., 2000). Its expression is regulated by many different hormones and growth 
factors, like PTH, vitamin D3, EGF, TGF-βs and many more. Additionally, it has 
been shown that OPN is involved in many functions during development, bone 
remodeling, calcification, homeostasis and immunoprotection (SODEK et al., 
2000). OPN is also secreted by osteoclasts and influences osteoclast function and 
bone resorption (REINHOLT et al., 1990; CHELLAIAH et al., 2003). The most 
important function of this protein seems to be a potent inhibitory role in 
calcification (HUNTER et al., 1994; ZHOU et al., 2012) due to its potent ability to 
bind mineral crystals (SODEK et al., 2000). This gene was detected in 1 week and 
4 weeks groups. Enpp1, another gene that has been detected as up-regulated, is 
known to have direct influence on the expression of Spp1/Opn (see below). As Spp1 
is expressed by both osteoblasts and osteoclasts, conclusions about its effects on 
bone formation versus bone resorption are difficult to reach. 
SLIT2 is a protein which has been identified as an important factor for axon 
migration and stimulation, but has also inhibitory effects on axons (BROSE & 
TESSIER-LAVIGNE, 2000). Recently, there has also been a report describing Slit2 
expression in osteoblasts. This study revealed that, in vitro, SLIT2 inhibited the 
differentiation of osteoblasts (SUN et al., 2009). This gene has also been detected 
both in the 1 week and in the 4 weeks groups.  
DCSTAMP, a seven-pass transmembrane protein, was identified as the key 
regulator of osteoclast cell-to-cell fusion (YAGI et al., 2005). This gene has only 
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been detected as differentially regulated in the 1 week group. Deletion of this gene 
prevents the fusion of pre-osteoclasts to the active multinucleated mature osteoclast, 
and DCSTAMP knockout mice were found to have higher bone mass (YAGI et al., 
2005). Mice overexpressing DCSTAMP showed accelerated bone resorption and 
less bone mass (IWASAKI et al., 2008; CHIU et al., 2012). However, a ligand 
mediating these effects has not yet been detected (CHIU et al., 2012). Interestingly, 
this gene has been found to be up-regulated in our microarray analysis, whereas the 
qRT-PCR analysis revealed that the expression of this gene was unchanged in 
Col1(I)-AREG-transgenic mice. What one would expect is a down-regulation of 
this gene in the 1 week group, as the transgenic animals have a higher bone mass 
than the wild-type controls, and a decrease in osteoclast number was observed. The 
results of the qRT-PCR analysis seem to be more in accordance with the observed 
phenotype of the Col1(I)-AREG-transgenic mouse line than the microarray analysis 
result. This issue will be discussed further below. 
The proteolytic enzyme MMP9 (other names: gelatinase B/type IV collagenase), 
only detected for the 1 week group, is expressed in osteoclasts and has an 
established function is the degradation of extracellular matrix in bone and in various 
other tissues (REPONEN et al., 1994; SUNDARAM et al., 2007). MMP9 is up-
regulated by RANKL (SUNDARAM et al., 2007) and other studies revealed that 
TNF-α stimulated osteoblast-like MC3T3-E1 cells also express MMP9 in response 
to inflammatory processes (TSAI et al., 2014). Like Dcstamp, Mmp9 has been 
detected as an up-regulated gene by our microarray analysis, but as unchanged by 
qRT-PCR analysis. Again, the result of the qRT-PCR seems to fit more with the 
phenotype of the Col1(I)-AREG-transgenic mouse line, although because of the 
observed decrease in osteoclast-number in this mouse line, one would rather expect 
a down-regulation of this gene. 
Another potentially interesting gene is Enpp1 (also known as PC-1: plasma cell 
membrane glycoprotein 1). It was detected in both the 1 week and the 4 weeks 
groups. The protein coded by this gene is an extracellular and intracellular active 
enzyme, which hydrolyzes phosphodiester bonds. It is expressed in many tissues of 
the body and in high levels in vascular smooth muscle cells, osteoblasts and 
chondrocytes (HUANG et al., 1994; MACKENZIE et al., 2012). This enzyme is 
involved indirectly in the mineralization of bones. It mainly produces inorganic 
pyrophosphate (PPi) by hydrolyzing ATP to AMP, and to a lesser extent inorganic 
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phosphate (Pi) by hydrolysis of ADP to AMP (MACKENZIE et al., 2012). PPi 
inhibits mineralization effectively by its capacity of binding to hydroxyapatite 
crystals, thus preventing further crystal growth. A decrease of extracellular PPi 
leads to increased mineralization by an elevated deposition of hydroxyapatites, 
whereas an increase of PPi results in decrease of mineralization (ADDISON et al., 
2007). Additionally, there have been reports that Enpp1 also functions as a 
stimulator for osteoblast differentiation, and might also be able to enhance 
osteoblastic gene expression (NAM et al., 2011). Spp1/Opn, which has also been 
detected as an up-regulated gene by microarray analysis (see above) is another 
potent mineralization inhibitor, and is influenced directly by the expression of 
Enpp1. A mouse line deficient for Enpp1 also showed decreased Spp1/OPN 
expression (JOHNSON et al., 2003). The cooperation between Enpp1 and 
SPP1/OPN is considered to have a synergistic effect on the inhibition of 
mineralization by binding hydroxyapatite (JOHNSON et al., 2003; ADDISON et 
al., 2007; ZHOU et al., 2012). Possibly, an up-regulation of these genes might be 
an indicator of the beginning of an elevated osteoclastogenesis and therefore bone 
resorption. But they might also be up-regulated in answer to an elevated osteoblast 
function.  
There are two genes that had only been detected for the 4 weeks group: Prrx1 and 
Prrx2. Prrx (paired-related homeobox) has been known to play a role in limb bud 
development (NOHNO et al., 1993; MARTIN & OLSON, 2000). More recently, a 
study revealed that Prrx1b (one of the two isoforms of Prrx1) and Prrx2 mediate 
inhibition of osteoblast differentiation via TNF-α, by inhibition of Runx2 and Osx 
(LU et al., 2011). TNF-α, in turn, is known to stimulate the expression of RANKL 
and M-CSF and therefore to initiate osteoclastogenesis (BOYCE et al., 2005; LU 
et al., 2011). Prrx1 was reported to be expressed during embryonic development up 
to day E11.5, with much lower levels thereafter (LU et al., 2011). Interestingly, a 
similar effect of decreasing osteoblast differentiation via down-regulation of Runx2 
and Osx was reported for EGFR-signaling in bone (ZHU et al., 2011). As Prrx1 and 
Prrx2 had been found to be up-regulated in the 4 weeks group, this might be an 
indicator of the beginning of elevated osteoclastogenesis. This would also be in 
accordance with the observations for the phenotype of the Col1(I)-AREG mouse 
line, as all the observed effects in the bone phenotype disappear with increasing 
age. 
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Some of the detected genes have not been reported yet to have a specific role in 
bone homeostasis, but might nevertheless be interesting: Map1b (microtubule 
associated protein 1b) is expressed mainly in the nervous system and promotes 
microtubule development; its expression level is higher in childhood, than in adults 
(VILLARROEL-CAMPOS & GONZALEZ-BILLAULT, 2014). Cdkn2a (known 
under many different names like p16, INK4, ARF, among others) is a potent tumor 
suppressor gene (LOWE & SHERR, 2003). TIMP1 belongs to the family of tissue 
inhibitors of metalloproteinases. It inhibits matrix-metalloproteinases like, for 
example, MMP9, and it promotes the proliferation of several different cell types 
(RIES, 2014).  
For the differentially expressed down-regulated genes for the 1 week group, the 
GO-analysis yielded results in the categories hematopoiesis and immune system 
development. There had been no reports for Areg influencing the development of 
hematopoietic or immune cells so far (BERASAIN & AVILA, 2014). Only one of 
the detected up-regulated genes, Cdkn2a/p16, was reported to possibly influence 
the physiologic quiescence of hematopoietic stem cells (EZOE et al., 2004). This 
might explain the detection of the down-regulation of genes concerning 
hematopoiesis. As this effect could only be observed for the 1 week group (the list 
of differentially expressed down-regulated genes for the 4 weeks group contained 
only very few genes), it may simply represent a transient effect. 
When assessing these in parts contradictory results from our transcriptome analysis, 
the reliability of the used technology has also to be taken into account. Our 
transcriptome analysis was conducted via microarrays, whose principle is 
hybridization of the transcript of the isolated RNA to a “probe” immobilized on the 
microarray chip. However, this method is not infallible. In fact, there is a number 
of error sources which can affect the obtained results. There are for example cross 
hybridizations between similar sequences, high signal-to-noise ratios, which leads 
to the problem that lowly expressed genes might not be detected, or conversely, 
hybridization saturation which prevents an accurate detection of highly expressed 
genes (HURD & NELSON, 2009; SIRBU et al., 2012). These error sources might 
either lead to false positive or false negative signals, which have great influence on 
the obtained results. Regarding the different results obtained with microarray 
analysis and qRT-PCR, the question is which results are more reliable. In many 
experiments, qRT-PCR is used for validation of microarray analysis, because of the 
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high sensitivity to quantify genes (STANTON, 2001; WONG & MEDRANO, 
2005; SHI et al., 2006). Although the transcriptome analysis via microarray has 
been criticized for its sometimes poor reproducibility, a quality analysis project 
indicated a satisfactory correlation between the results of different microarray 
platforms and other gene expression technologies, like TaqMan (SHI et al., 2006), 
even if the correlation is never perfect. Thus, it might be simply a coincidence that 
false positive genes (Dcstamp and Mmp9) were selected for qRT-PCR. Because of 
the higher sensitivity of qRT-PCR and the phenotype of the Col1(I)-AREG mouse 
line, it seems more likely that the qRT-PCR results are the genuine ones. 
Our analysis revealed that the effect of AREG overexpression on the osteoblast 
transcriptome is definitively age-dependent, which is in accordance with the 
phenotype of this mouse line. What are the explanations for this phenomenon? Our 
microarray analysis revealed that genes involved in osteoclastogenesis, such as 
Dcstamp and Mmp9 are up-regulated, though these results could not be confirmed 
by the qRT-PCR analysis. The levels of Rankl and Opg have been detected by qRT-
PCR to be unchanged for the transgenic mice of the 1 week group in comparison to 
the wild-types. To detect a regulation of genes involved in osteoclastogenesis would 
have been particularly interesting. On the one hand, because of the observed 
phenotype for this mouse line (decreased number of osteoclasts), and on the other 
hand, because it has been described, that genes involved in osteoclastogenesis are 
paradoxically up-regulated with an anabolic PTH regime (KOH et al., 2005; LI et 
al., 2007a; LI et al., 2007b). A study examining the gene expression of continuous 
(catabolic effect) or intermittent (anabolic effect) PTH treatment identified a down-
regulation of Opg, and an up-regulation of Rankl as a response to intermittent PTH 
treatment (LI et al., 2007a). Interestingly, the same study found, that continuous 
PTH treatment (catabolic regime) did not increase the stimulation of genes involved 
in osteoclastogenesis (LI et al., 2007a). It has been described, that activation of the 
EGFR in bone leads to a decrease of OPG, therefore inducing an unbalance between 
RANKL and OPG in favor for RANKL and leading to increased osteoclastogenesis 
(ZHU et al., 2007; LYNCH, 2011). The ratio RANKL/OPG has been described to 
be more relevant for osteoclastogenesis than total levels of up- or down-regulation 
for each gene (LI et al., 2007a). Interestingly, OPG has been found to be an inhibitor 
of the anabolic function of PTH (KOH et al., 2005), although it is the antagonist of 
RANKL, a stimulator of osteoclastogenesis.  
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Our results confirm a bone anabolic effect of Areg via the EGFR, yet this effect 
seems to be compensated by unknown mechanisms with increasing age. 
Furthermore, an alteration of the expression of genes regulating osteoclastogenesis 
mediated by bone specific up-regulation of Areg could not be satisfactorily proven.  
The mechanism behind the age-dependent anabolic function of Areg on bone will 
need further investigation. The Col1(I)-AREG mouse line exhibits a permanent up-
regulation of Areg, but an anabolic function with PTH treatment is only achieved 
when PTH is given intermittently. This might possibly be the reason why the effect 
of an initially higher bone mass of this mouse line disappears with increased age. A 
possible explanation might be the involvement of a feedback or rebound loop, as is 
known for several other biological processes mediated by hormones, like, for 
example, the ovarian cycle (MESSINIS, 2006). As these results were obtained via 
microarray analysis, and this technology has a number of limitations, it seems to be 
worth to examine the effects in this transgenic mouse line with newer and more 
sensitive methods for all age-groups. The method of choice would be an analysis 
with the new RNA-Seq technology (Next or Second Generation Sequencing). 
RNA-Seq has many advantages in comparison to the microarray technology. This 
new technology is becoming increasingly affordable and would currently be the 
technology of choice for transcriptome analyses. Unlike microarrays, RNA-Seq 
works without hybridization, which is, as mentioned above, a major source for 
various errors. In contrast, the isolated RNA is sequenced directly by RNA-Seq, 
and the reads are counted (WANG et al., 2009). This method has other additional 
advantages compared to microarrays: No known compatible sequence is needed for 
the detection of transcripts, and RNA-Seq has a higher dynamic range in detecting 
transcripts either with a very high or low expression rate (WANG et al., 2009). 
1.4. Final considerations 
Areg is a very interesting gene whose role in bone metabolism deserves further 
studies. It definitively promotes bone anabolism, yet its effect seems to be age-
dependent. Our analysis revealed that genes involved in bone homeostasis, like 
Slit2, Enpp1, Spp1/Opn, and some others, are regulated as a consequence of Areg-
up-regulation. Several genes regulating osteoclastogenesis have been detected via 
microarrays to be regulated by an osteoblast-specific overexpression of Areg, 
though not by qRT-PCR for the 1 week group. Intermittent PTH treatment has 
been reported to promote an up-regulation of genes involved in osteoclastogenesis 
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(LI et al., 2007a). Whether Areg also has an effect on genes involved in 
osteoclastogenesis, could not be terminally verified, as our results were 
ambiguous. The paradoxical finding of an up-regulation of genes promoting 
osteoclastogenesis along with an anabolic effect on bone is a very interesting 
observation. As this transcriptome study could not ultimately clarify the role of 
Areg in influencing the genes involved in osteoclastogenesis, further examinations 
with newer and more sensitive methods will be needed. 
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VI. ZUSAMMENFASSUNG 
Osteoporose ist eine schwerwiegende Erkrankung, die rund ein Drittel aller 
postmenopausalen Frauen betrifft und auf Grund der erhöhten Frakturrate zu einer 
Verminderung der Lebensqualität der Betroffenen führt. PTH ist derzeit das 
einzig verfügbare Medikament für die Behandlung von Osteoporose mit anaboler 
Wirkung auf den Knochenaufbau. Der Wirkmechanismus ist bis heute ungeklärt. 
Areg, ein Ligand des EGFR, konnte als eines der Gene identifiziert werden, die 
durch PTH-Behandlung hochreguliert werden (QIN et al., 2005). Eine neue 
transgene Mauslinie, die Col1(I)-AREG-Linie, wurde generiert, um den Effekt 
von AREG auf den Knochenstoffwechsel untersuchen zu können. Diese 
Mauslinie zeichnet sich durch eine Osteoblasten-spezifische Überexprimierung 
von AREG aus. µCT und pQCT Untersuchungen  bestätigten eine signifikante 
Erhöhung der totalen Knochendichte des Femurs. Aus diesem Grund wurde eine 
Analyse des Transkriptoms für diese Mauslinie mittels Microarrays durchgeführt, 
mit dem Ziel, Abweichungen in der Genexpression zu entdecken, die dazu 
beitragen könnten, diesen knochenanabolen Effekt von Areg aufdecken zu 
können. Für die Analyse des Transkriptoms wurden drei Altersgruppen gewählt: 1 
Woche (neugeborene Mäuse), 4 Wochen (jugendliche Mäuse) und 8 Wochen 
(ausgewachsene Mäuse). Abweichungen in der Genexpression waren am stärksten 
nachweisbar für die 1 Wochen-Gruppe mit 47 hoch-, und 187 runterregulierten 
Genen. Mit steigendem Alter nahmen diese Abweichungen ab. Für die 4 Wochen-
Gruppe waren 8 runter- und 56 hochregulierte Gene nachweisbar und für die 8 
Wochen-Gruppe waren keine differentiell exprimierten Gene mehr nachweisbar. 
Die Listen der differentiell exprimierten Gene wurden mittels GO-Analyse 
untersucht, um nach überrepräsentierten Kategorien für diese Gene zu suchen und 
deren Zusammenhänge bildlich darstellen zu können. Unter den differentiell 
hochexprimierten Genen, für die bereits eine Funktion im Knochenstoffwechsel 
bekannt war, waren zum Beispiel Slit2, Enpp1, Spp1/Opn sowohl für die 1 
Wochen- als auch für die 4 Wochen-Gruppe, und Dcstamp und Mmp9 lediglich 
für die 1 Wochen-Gruppe. Diese Ergebnisse konnten mittels der zusätzlich für die 
1 Wochen-Gruppe durchgeführte qRT-PCR-Analyse nicht bestätigt werden: 
keines der untersuchten Gene (Dcstamp, Mmp9, Opg, Rankl) war statistisch 
signifikant reguliert. Es wurde beschrieben, dass Gene, die die Osteoklastogenese 
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vermitteln, durch intermittierende (also anabole) PTH-Behandlung hochreguliert 
werden (LI et al., 2007a). Wir konnten einen Einfluss der Osteoblasten-
spezifischen Überexprimierung von Areg auf die Regulierung entsprechender 
Gene nicht nachweisen, da sich die Ergebnisse der Microarrays und der qRT-PCR 
widersprachen. Es erscheint daher lohnend, den Einfluss von Areg auf den 
Knochenstoffwechsel mit neueren und sensitiveren Methoden wie RNA-Seq zu 
untersuchen.
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VII. SUMMARY 
Osteoporosis is a severe disease that affects around 1/3 of postmenopausal women 
and leads to an impaired quality of life, mainly due to an increased fracture rate. 
PTH is currently the only anabolic agent used for the treatment of osteoporosis. It 
remains unknown how this effect is mediated. Areg, a ligand of the epidermal 
growth factor receptor (EGFR) has been identified as a PTH target gene (QIN et 
al., 2005). A new transgenic mouse line, the Col1(I)-AREG mouse line, had been 
generated to examine the effect of AREG on bone homeostasis. This mouse line 
exhibits an osteoblast-specific over-expression of AREG. µCT and pQCT revealed 
a significant increase in total bone mineral density of the femur. Therefore, to 
examine alterations of gene expression that might help unravel this mechanism of 
an anabolic effect on bone by Areg, we conducted a bone transcriptome analysis 
using microarrays. Three age groups had been chosen for the transcriptome 
analysis: 1 week (newborn), 4 weeks (adolescent) and 8 weeks (adult). Gene 
expression alterations were highest in the 1 week group with 184 down-regulated 
genes and 47 up-regulated genes, and decreased with age with 8 down-regulated 
genes and 56 up-regulated genes in the 4 weeks group, and no detectable 
differentially expressed genes in the 8 weeks group. Lists of differentially expressed 
genes were then analyzed with a GO-analysis to search for overrepresented 
annotation terms and visualize the connections of the differentially expressed genes. 
Prominent genes among the differentially expressed up-regulated genes, with a 
known function in bone homeostasis were for example Slit2, Enpp1, Spp1/Opn for 
1 week and 4 weeks groups and Dcstamp and Mmp9 only for the 1 week group. 
qRT-PCR, conducted only for the 1 week group, unfortunately did not confirm the 
results obtained by our microarray analysis: none of the examined genes (Dcstamp, 
Mmp9, Opg, Rankl) had been detected as significantly regulated. Genes involved in 
osteoclastogenesis had been reported to be up-regulated by an intermittent PTH 
treatment (LI et al., 2007a). We were not able to verify an effect of the osteoblast-
specific up-regulation of Areg on the regulation of these genes, because the results 
of microarray and qRT-PCR analysis were ambiguous. Therefore, it seems worth 
to examine the role of Areg in bone homeostasis with newer and more sensitive 
methods like RNA-Seq. 
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3. Primer sequences 
3.1. PCR primer sequences 
Areg Xba#1: 5` -TAG TCT AGA TTG CTG CAG AGA CCG AGA C -3` 
Areg Pac#2: 5’ -TAG TTA ATT AAG GCA ATG ATT CAA CTT TTA CC -3`  
Errb2 fl up: 5’ -TTT ATG TGG GCA CGC TTA GAA C- 3‘ 
Erbb2 fl lw: 5’ -CTA GAA GTC TGA TTT GCG GTA T- 3‘  
3.2. qRT-PCR primer sequences 
mMMP9_1992_FW: 3` CGT CAT TCG CGT GGA TAA GG 5`    
mMMP9_2110_RV: 3` TTT GGA AAC TCA CAC GCC AG 5`    
mRANKL_673_FW: 3´ GAA ACA TCG GGA AGC GTA CC  5` 
mRANKL_782_RV: 3` TTC GTG CTC CCT CCT TTC AT 5` 
mOPG_488_FW: 3` ACA CGA ACT GCA GCA CAT TT 5` 
mOPG_582_RV: 3` CTT TTG CGT GGC TTC TCT 5´ 
mDCSTAMP_978_FW: 3` ACA GTT CCA AAG CTT GCC AG  5´ 
mDCSTAMP_1106_RV: 3`  GGT TTA GGA ATG CAG CTC GG 5` 
house keeping gene: 
mGAPDH_FW :  3` TCATCAACGGGAAGCCCATCAC  5`    
mGAPDH_RV: 3` AGACTCCACGACATACTCAGCACCG 5` 
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4. List of genes 
4.1. 1 week, differentially expressed up-regulated genes 
Gene Number 
Gene 
Symbol Gene Name 
Fold 
Change 
Adjusted 
p-value 
NM_009704 Areg Amphiregulin 207,074 0,000 
NM_029838 Col25a1 collagen, type XXV, alpha 1 3,514 0,005 
NM_010054 Dlx2 distal-less homeobox 2 3,317 0,007 
NM_009263 Spp1 secreted phosphoprotein 1 = 
Osteopontin 
3,143 0,007 
NM_007670 Cdkn2b cyclin-dependent kinase inhibitor 2B 3,091 0,005 
ENSMUST00000105520 Enpp1 ectonucleotide 
pyrophosphatase/phosphodiesterase 1 
2,942 0,005 
NM_009877 Cdkn2a cyclin-dependent kinase inhibitor 2A 2,868 0,007 
NM_019950 Chst5 carbohydrate (N-acetylglucosamine 6-
O) sulfotransferase 5 
2,868 0,007 
NM_011670 Uchl1 ubiquitin carboxy-terminal hydrolase 
L1  
2,774 0,005 
NM_198711 Col25a1 collagen, type XXV, alpha 1 transcript 
variant 2 
2,556 0,005 
NM_008815 Etv4 ets variant gene 4 (E1A enhancer 
binding protein, E1AF) 
2,533 0,007 
NM_018857 Msln mesothelin 2,504 0,005 
NM_008634 Map1b microtubule-associated protein 1B 2,469 0,007 
NM_028325 Zcchc12 zinc finger, CCHC domain containing 12 2,457 0,007 
NM_001001979 Megf10 multiple EGF-like-domains 10 2,445 0,005 
NM_008813 Enpp1 ectonucleotide 
pyrophosphatase/phosphodiesterase 1 
2,428 0,007 
NM_008872 Plat plasminogen activator, tissue 2,385 0,008 
NM_008926 Prkg2 protein kinase, cGMP-dependent, type 
II  
2,344 0,007 
chr5:152006587-
152008784_R 
 n.c. (non coding) 2,264 0,007 
chr5:152006587-
152008784_R 
 n.c. 2,263 0,005 
NM_009115 S100b S100 protein, beta polypeptide, neural 2,247 0,009 
chr5:152006587-
152008784_R 
 n.c. 2,219 0,007 
NM_010181 Fbn2 fibrillin 2  2,198 0,007 
NM_153800 Arhgap22 Rho GTPase activating protein 22 2,167 0,007 
NM_013599 Mmp9 matrix metallopeptidase 9 2,157 0,007 
NM_029770 Unc5b unc-5 homolog B (C. elegans) 2,151 0,007 
chr5:14943275-
14944205_F 
 n.c. 2,149 0,019 
NM_024474 Col26a1 collagen, type XXVI, alpha 1 2,149 0,008 
NM_008815 Etv4 ets variant gene 4 (E1A enhancer 
binding protein, E1AF) 
2,145 0,018 
NM_178804 Slit2 slit homolog 2 (Drosophila)  2,139 0,007 
NM_026838 Srpx2 sushi-repeat-containing protein, X-
linked 2, transcript variant 1 
2,123 0,007 
NM_029422 Dcstamp dentrocyte expressed seven 
transmembrane protein 
2,086 0,007 
NM_173770 Fam69c family with sequence similarity 69, 
member C 
2,082 0,007 
NM_001044384 Timp1 tissue inhibitor of metalloproteinase 1, 
transcript variant 1 
2,071 0,005 
chr5:15146475-
15170100_F 
 n.c. 2,069 0,037 
NM_015755 Hunk hormonally upregulated Neu-
associated kinase 
2,062 0,007 
NM_008100 Gcg glucagon 2,048 0,007 
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Gene Number 
Gene 
Symbol Gene Name 
Fold 
Change 
Adjusted 
p-value 
chr5:15146475-
15170100_F 
 n.c. 2,041 0,019 
NM_010181 Fbn2 fibrillin 2 2,032 0,007 
NM_009324 Tbx2 T-box 2 2,027 0,008 
chr13:56851404-
56851796_R 
 n.c. 2,021 0,019 
chr13:56851404-
56851796_R 
 n.c. 2,018 0,007 
NM_001164763 Rarres1 retinoic acid receptor responder 
(tazarotene induced) 1 
2,013 0,007 
NM_172864 Wdr63 WD repeat domain 63 2,013 0,008 
NM_010373 Gzme granzyme E 2,010 0,011 
NM_010737 Klrb1a killer cell lectin-like receptor subfamily 
B member 1A, transcript variant 1 
2,007 0,011 
NM_028775 Cyp2s1 cytochrome P450, family 2, subfamily s, 
polypeptide 1 
2,007 0,007 
AK019926  adult male pituitary gland cDNA, RIKEN 
full-length enriched library 
2,006 0,008 
 
4.2. 1 week, differentially expressed, down-regulated genes 
Gene Number 
Gene  
Symbol Gene Name 
Fold 
Change 
Adjusted 
p-value 
NM_010815 Grap2 GRB2-related adaptor protein 2 0,500 0,010 
chr10:69819062-
69871640_F 
 n.c. 0,500 0,009 
NM_152823 Unc5cl unc-5 homolog C (C. elegans)-like 0,500 0,026 
chr2:153325670-
153352170_R 
 n.c. 0,499 0,048 
A_55_P1958902  n.c. 0,499 0,007 
chr16:89961600-
89971725_R 
 n.c. 0,498 0,007 
NM_007998 Fech ferrochelatase 0,498 0,007 
NM_172577 Slc25a21 solute carrier family 25 (mitochondrial 
oxodicarboxylate carrier), member 21, 
transcript variant 1 
0,498 0,007 
NM_011465 Spta1 spectrin alpha, erythrocytic 1 0,498 0,007 
NM_011527 Tal1 T cell acute lymphocytic leukemia 1 0,498 0,008 
AK048886  0 day neonate cerebellum cDNA 0,497 0,011 
NM_008185 Gstt1 glutathione S-transferase, theta 1 0,497 0,007 
NM_022986 Irak1bp1 interleukin-1 receptor-associated 
kinase 1 binding protein 1, transcript 
variant 1 
0,497 0,011 
chr15:84737071-
84744158_F 
 n.c. 0,497 0,020 
NM_009479 Uros uroporphyrinogen III synthase 0,497 0,007 
XM_621386 Gm5958 predicted pseudogene 5958 0,497 0,010 
NM_139303 Kif18a kinesin family member 18A 0,496 0,007 
NM_001142952 Fam46c family with sequence similarity 46, 
member C 
0,496 0,009 
NM_029264 Ttll10 tubulin tyrosine ligase-like family, 
member 10 
0,496 0,007 
ENSMUST00000103526 Ighv1-55-
201 
immunoglobulin heavy variable 1-55 0,495 0,030 
chr5:77084398-
77086144_R 
 n.c. 0,495 0,007 
NM_001081349 Slc43a1 solute carrier family 43, member 1 
(Slc43a1), transcript variant 1 
0,495 0,008 
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ENSMUST00000111637 Ube2l6-
202 
ubiquitin-conjugating enzyme E2L 6 
Gene 
0,494 0,007 
chr8:83210957-
83219451_F 
 n.c. 0,494 0,007 
NM_183173 Sowaha sosondowah ankyrin repeat domain 
family member A  
0,494 0,007 
ENSMUST00000045307  n.c. 0,494 0,010 
NM_001033286 Slc30a10 solute carrier family 30, member 10 0,494 0,018 
NM_001008499 Taar4 trace amine-associated receptor 4 0,493 0,044 
NM_001013784 E130309D
14Rik 
RIKEN cDNA E130309D14 gene 0,492 0,009 
NM_177733 E2f2 E2F transcription factor 2 0,491 0,007 
NM_008135 Slc6a9 solute carrier family 6 
(neurotransmitter transporter, glycine), 
member 9 
0,491 0,008 
NM_011722 Dctn6 dynactin 6  0,491 0,007 
NM_026331 Slc25a37 solute carrier family 25, member 37 0,491 0,008 
NM_138955 Abcg4 ATP-binding cassette, sub-family G 
(WHITE), member 4  
0,491 0,010 
NM_001177731 Mrap2 melanocortin 2 receptor accessory 
protein 2 (Mrap2), transcript variant 1 
0,491 0,024 
ENSMUST00000103469 Ighv14-3-
001 
immunoglobulin heavy variable V14-3 0,491 0,010 
ENSMUST00000050753  Transcript: A930002H24Rik-201  0,490 0,040 
NM_031880 Tnk1 tyrosine kinase, non-receptor, 1 0,490 0,007 
NM_134021 Pnpo pyridoxine 5'-phosphate oxidase 0,490 0,007 
NM_001159626 Hagh hydroxyacyl glutathione hydrolase 
(Hagh), transcript variant 2 
0,490 0,008 
NM_011270 Rhd Rh blood group, D antigen 0,489 0,007 
chr6:052032838-
052033444 
 n.c. 0,489 0,031 
NM_011269 Rhag Rhesus blood group-associated A 
glycoprotein 
0,489 0,008 
NM_144533 Nmnat3 nicotinamide nucleotide 
adenylyltransferase 3 
0,489 0,007 
NM_007570 Btg2 B cell translocation gene 2, anti-
proliferative 
0,489 0,008 
NM_008114 Gfi1b growth factor independent 1B, 
transcript variant 1 
0,488 0,007 
NM_025912 Fam210b family with sequence similarity 210, 
member B 
0,488 0,008 
XM_003086781  n.c. 0,488 0,015 
BC003861 cDNA 
clone 
MGC:6604 
IMAGE:34
87642 
hydroxymethylbilane synthase, mRNA 
(cDNA clone MGC:6604 
IMAGE:3487642), complete cds 
0,488 0,009 
NM_029964 6030468B
19Rik 
RIKEN cDNA 6030468B19 gene 0,488 0,007 
NM_009514 Vpreb3 pre-B lymphocyte gene 3 0,488 0,008 
NM_144869 BC021614 cDNA sequence BC021614 0,487 0,011 
NM_001029872 Itgad integrin, alpha D 0,487 0,013 
chr4:155585650-
155608700_R 
 n.c. 0,487 0,016 
NM_019687 Slc22a4 solute carrier family 22 (organic cation 
transporter), member 4  
0,486 0,007 
ENSMUST00000022711  RIKEN cDNA 4930449E01 gene 0,485 0,008 
ENSMUST00000065159  n.c. 0,484 0,009 
ENSMUST00000103537 Ighv1 immunoglobulin heavy variable 1-66 0,484 0,021 
NM_027464 Fam213a family with sequence similarity 213, 
member A 
0,484 0,007 
NM_008102 Gch1 GTP cyclohydrolase 1 0,483 0,007 
A_55_P1976450  n.c. 0,483 0,021 
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ENSMUST00000103410 Igkc immunoglobulin kappa constant  0,483 0,046 
NM_001038699 Fn3k fructosamine 3 kinase, transcript 
variant 2 
0,483 0,019 
NM_020583 Isg20 interferon-stimulated protein, 
transcript variant 1 
0,483 0,007 
ENSMUST00000107465  n.c. 0,482 0,009 
NM_008089 Gata1 GATA binding protein 1 0,482 0,008 
NM_001013368 E2f8 E2F transcription factor 8 0,481 0,009 
NM_011638 Tfrc transferrin receptor 0,481 0,007 
NM_146173 Tspan33 tetraspanin 33 0,481 0,007 
chr9:40029344-
40050160_F 
 n.c. 0,479 0,018 
NM_009653 Alas2 aminolevulinic acid synthase 2, 
erythroid (Alas2), transcript variant 1 
0,479 0,008 
XR_105911  Redrum, erythroid developmental long 
intergenic non-protein coding 
transcript (Redrum), non-coding RNA 
0,479 0,008 
NM_009345 Dntt deoxynucleotidyltransferase, terminal, 
transcript variant 1 
0,477 0,013 
chr8:122807653-
122823000_R 
 n.c. 0,476 0,014 
NM_197999 Ces2g carboxylesterase 2G 0,476 0,007 
NM_001177416 Gm6792 predicted gene 6792, transcript variant 
1 
0,476 0,008 
chr6:145936225-
145965575_F 
 n.c. 0,475 0,007 
chr13:81773237-
81783062_F 
 n.c. 0,474 0,007 
NM_011403 Slc4a1 solute carrier family 4 (anion 
exchanger), member 1 
0,474 0,008 
chr2:118408095-
118415745_F 
 n.c. 0,473 0,012 
NM_009699 Aqp2 aquaporin 2 0,473 0,024 
NM_026527 Chac2 ChaC, cation transport regulator 2 0,472 0,007 
NM_146010 Tspan8 tetraspanin 8 (Tspan8), transcript 
variant 1 
0,471 0,007 
NM_001110320 Cd72 CD72 antigen (Cd72), transcript variant 
1 
0,471 0,009 
NM_013514 Dmtn dematin actin binding protein (Dmtn), 
transcript variant 2 
0,470 0,007 
NM_009973 Csn1s2b casein alpha s2-like B 0,470 0,008 
AK020830  adult retina cDNA, RIKEN full-length 
enriched library, clone:A930008G19 
product:HYPOTHETICAL PROTEIN 
KIAA0140 homolog [Homo sapiens], 
full insert sequence 
0,470 0,007 
chr10:66349796-
66378261_R 
 n.c. 0,469 0,017 
chr5:35893909-
35899497_R 
 n.c. 0,468 0,007 
chr9:89167172-
89168980_F 
 n.c. 0,467 0,012 
NM_010635 Klf1 Kruppel-like factor 1 (erythroid) 0,467 0,011 
NM_001033301 Fhdc1 FH2 domain containing 1, transcript 
variant 2 
0,467 0,009 
NM_010149 Epor erythropoietin receptor 0,467 0,007 
NM_001164557 Pdzk1ip1 PDZK1 interacting protein 1, transcript 
variant 1 
0,467 0,009 
NM_001195094 Ccdc42b coiled-coil domain containing 42B 0,467 0,014 
NM_001037634 Oosp2 oocyte secreted protein 2 0,466 0,007 
ENSMUST00000109709  RIKEN cDNA 1700003F12 gene 0,464 0,008 
NM_020583 Isg20 interferon-stimulated protein, 
transcript variant 1 
0,464 0,007 
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NM_172479 Slc38a5 solute carrier family 38, member 5  0,464 0,008 
NM_001042451 Snca synuclein, alpha (Snca), transcript 
variant 1 
0,463 0,007 
AK047639  adult male corpus striatum cDNA, 
RIKEN full-length 
0,463 0,008 
NM_001199971 Tac2 tachykinin 2, transcript variant 2 0,463 0,026 
NM_007799 Ctse cathepsin E  0,463 0,007 
NM_020504 Cldn13 claudin 13 0,462 0,009 
NM_175000 Hbq1a hemoglobin, theta 1A 0,460 0,007 
NM_177564 Dhrs11 dehydrogenase/reductase (SDR family) 
member 11 
0,460 0,012 
NM_001167746 Dnah17 dynein, axonemal, heavy chain 17 0,459 0,009 
chr12:32781477-
32808567_R 
 n.c. 0,458 0,007 
NM_145981 Phyhip phytanoyl-CoA hydroxylase interacting 
protein 
0,457 0,017 
NM_001131020 Gfap  glial fibrillary acidic protein (Gfap), 
transcript variant 1 
0,456 0,008 
XM_003085972 Gm10362 predicted gene 10362 0,456 0,031 
NM_023892 Icam4 intercellular adhesion molecule 4, 
Landsteiner-Wiener blood group  
0,455 0,009 
NM_030069 Nxpe2 neurexophilin and PC-esterase domain 
family, member 2 
0,455 0,007 
NM_178667 Tfdp2 transcription factor Dp 2, transcript 
variant 1 
0,455 0,007 
chr5:149765314-
149771786_R 
 n.c. 0,454 0,007 
chr15:101084597-
101095097_F 
 n.c. 0,453 0,007 
NM_172709 Otop1 otopetrin 1 0,453 0,007 
chr12:32781477-
32808567_R 
 n.c. 0,452 0,008 
NM_178715 Tmem30b transmembrane protein 30B 0,452 0,009 
NM_027600 4921504E
06Rik 
RIKEN cDNA 4921504E06 gene 0,452 0,014 
NM_011465 Spta1 spectrin alpha, erythrocytic 1  0,452 0,007 
XM_356935  n.c. 0,450 0,007 
NM_028025 Mageb16 melanoma antigen family B, 16, 
transcript variant 1 
0,450 0,008 
NM_032540 Kel Kell blood group 0,449 0,007 
NM_013848 Ermap erythroblast membrane-associated 
protein 
0,449 0,008 
chr5:122982442-
123000053_F 
 n.c. 0,449 0,007 
ENSMUST00000152722 Sult5a1 sulfotransferase family 5A, member 1 0,448 0,008 
NM_001164557 Pdzk1ip1 PDZK1 interacting protein 1, transcript 
variant 1 
0,448 0,008 
NM_011312 S100a5 S100 calcium binding protein A5 0,446 0,009 
NM_138678 Btnl10 butyrophilin-like 10 0,445 0,008 
ENSMUST00000034133 Mylk3 myosin light chain kinase 3  0,445 0,005 
XR_105468 5430401H
09Rik 
n.c. 0,444 0,008 
XR_106478  n.c. 0,440 0,014 
NM_011280 Trim10 tripartite motif-containing 10 0,437 0,007 
NM_022014 Fn3k fructosamine 3 kinase, transcript 
variant 1 
0,437 0,007 
NM_013848 Ermap erythroblast membrane-associated 
protein 
0,436 0,008 
chr12:32781477-
32808567_R 
 n.c. 0,434 0,008 
chr15:85412264-
85549139_F 
 n.c. 0,433 0,018 
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NM_016975 Gja3 gap junction protein, alpha 3, transcript 
variant 1 
0,433 0,022 
NM_175684 Fchsd1 FCH and double SH3 domains 1 0,431 0,009 
NM_019991 Prl2a1 prolactin family 2, subfamily a, 
member 1  
0,430 0,015 
NM_023117 Cdc25b cell division cycle 25B, transcript 
variant 1 
0,428 0,008 
NM_013513 Epb4.2 erythrocyte protein band 4.2 0,427 0,007 
NM_026875 Ypel3 yippee-like 3 (Drosophila) 0,426 0,008 
chr17:22420025-
22457650_F 
 n.c. 0,425 0,012 
NM_001080943 Zdhhc22 zinc finger, DHHC-type containing 22 0,425 0,007 
NM_001033981 Hbq1b hemoglobin, theta 1B 0,423 0,006 
NM_013467 Aldh1a1 aldehyde dehydrogenase family 1, 
subfamily A1 
0,421 0,010 
NM_011439 Sox13 SRY-box containing gene 13 0,417 0,009 
NR_033575 Gm12839 predicted gene 12839, non-coding RNA 0,416 0,009 
NM_019866 Spib Spi-B transcription factor (Spi-1/PU.1 
related)  
0,415 0,012 
ENSMUST00000109705  n.c. 0,412 0,014 
NM_027918 1300017J0
2Rik 
RIKEN cDNA 1300017J02 gene 0,410 0,008 
NM_010369 Gypa glycophorin A 0,407 0,007 
NM_145141 Fcrla Fc receptor-like A 0,404 0,013 
A_55_P2028214  n.c. 0,404 0,007 
NM_001034866 Pnldc1 poly(A)-specific ribonuclease (PARN)-
like domain containing 1  
0,402 0,046 
NM_026132 Txndc8  thioredoxin domain containing 8 0,400 0,038 
NM_001174086 Shisa9 shisa homolog 9 (Xenopus laevis), 
transcript variant 2 
0,397 0,033 
chr2:77146893-
77155643_F 
 n.c. 0,384 0,005 
chr11:69185658-
69186082_F 
 n.c. 0,384 0,017 
chr8:106037800-
106070025_F 
 n.c. 0,382 0,008 
chr1:36086491-
36087863_R 
 n.c. 0,380 0,007 
ENSMUST00000124863  n.c. 0,379 0,009 
NM_139142 Slc6a20a  solute carrier family 6 
(neurotransmitter transporter), 
member 20A 
0,373 0,007 
NM_001127354 Gm11938 predicted gene 11938 0,372 0,009 
NM_030180 Usp54 ubiquitin specific peptidase 54 0,362 0,009 
NM_001011749 Olfr704 olfactory receptor 704 0,360 0,010 
ENSMUST00000101091  n.c. 0,356 0,007 
NM_027802 Obox1 oocyte specific homeobox 1 0,355 0,033 
chr12:5303823-
5379098_R 
 n.c. 0,354 0,014 
NM_008102 Gch1 GTP cyclohydrolase 1 0,347 0,007 
NM_001109985 Nos1ap nitric oxide synthase 1 (neuronal) 
adaptor protein, transcript variant 1 
0,331 0,007 
ENSMUST00000132717 Mbd5 methyl-CpG binding domain protein 5  0,328 0,007 
chr8:94841965-
94881130_R 
 n.c. 0,320 0,008 
NR_015605 2900052N
01Rik 
RIKEN cDNA 2900052N01 gene 
(2900052N01Rik), long non-coding RNA 
0,311 0,011 
chr10:60473030-
60535340_R 
 n.c. 0,311 0,012 
chr9:96635508-
96654148_R 
 n.c. 0,308 0,010 
NM_001146351 Ephb6 Eph receptor B6, transcript variant 1 0,308 0,010 
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chr9:31834945-
32015745_R 
 n.c. 0,304 0,009 
chrX:20570399-
20571162_F 
 n.c. 0,298 0,008 
NAP092838-001  n.c. 0,288 0,009 
ENSMUST00000108646  n.c. 0,252 0,008 
TC1683061  Very low-density lipoprotein receptor 
variant (Fragment), partial (7%) 
[TC1683061] 
0,166 0,007 
 
4.3. 4 weeks, differentially expressed up-regulated genes 
Gene Number 
Gene 
Symbol Gene Name 
Fold 
Change 
Adjusted 
p-value 
NM_009704 Areg Amphiregulin 94,092 0,000 
NM_009877 Cdkn2a cyclin-dependent kinase inhibitor 2A 3,329 0,003 
NM_018857 Msln mesothelin 2,965 0,003 
NM_029838 Col25a1 collagen, type XXV, alpha 1 2,674 0,003 
NM_007670 Cdkn2b cyclin-dependent kinase inhibitor 2B 
(p15, inhibits CDK4) 
2,650 0,003 
NM_009263 Spp1 secreted phosphoprotein 1 2,610 0,003 
NM_001001979 Megf10 multiple EGF-like-domains 10 2,603 0,003 
NM_010180 Fbln1 fibulin 1 2,497 0,003 
NM_008634 Map1b microtubule-associated protein 1B 2,464 0,003 
NM_019950 Chst5 carbohydrate (N-acetylglucosamine 6-
O) sulfotransferase 5 
2,445 0,003 
NM_010181 Fbn2 fibrillin 2 2,393 0,008 
NM_008481 Lama2 laminin, alpha 2 2,383 0,008 
NM_033592 Pcdhga9 protocadherin gamma subfamily A, 9 2,320 0,003 
ENSMUST00000105520 Enpp1 ectonucleotide 
pyrophosphatase/phosphodiesterase 1 
2,291 0,003 
NM_008481 Lama2 laminin, alpha 2 2,245 0,021 
NM_010181 Fbn2 fibrillin 2 2,221 0,004 
NM_001044384 Timp1 tissue inhibitor of metalloproteinase 1 2,219 0,003 
NM_008872 Plat plasminogen activator, tissue 2,213 0,008 
NM_053110 Gpnmb glycoprotein (transmembrane) nmb 2,207 0,003 
NM_178804 Slit2 slit homolog 2  2,186 0,003 
NM_007739 Col8a1 collagen, type VIII, alpha 1 2,161 0,005 
AI428898 mp51g11.
x1 
n.c. (non coding) 2,158 0,003 
NM_138686 Cys1 cystin 1 2,145 0,044 
NM_010140 Epha3 Eph receptor A3 2,145 0,003 
NM_026838 Srpx2 sushi-repeat-containing protein, X-
linked 2 
2,144 0,003 
AK009210  unclassifiable, full insert sequence 2,133 0,007 
NM_176954 Celf5 CUGBP, Elav-like family member 5 2,132 0,004 
chr19:5834117-
5835940_R 
 n.c. 2,127 0,004 
NM_011670 Uchl1 ubiquitin carboxy-terminal hydrolase 
L1 
2,111 0,009 
AK048087  unclassifiable, full insert sequence 2,104 0,027 
NM_009116 Prrx2 paired related homeobox 2 2,101 0,018 
NM_010171 F3 coagulation factor III 2,095 0,003 
NM_011607 Tnc tenascin C 2,082 0,003 
chr5:152006587-
152008784_R 
 n.c. 2,081 0,003 
chr5:152006587-
152008784_R 
 n.c. 2,076 0,003 
NM_198711 Col25a1 collagen, type XXV, alpha 1 2,075 0,003 
NM_177588 Thnsl1 threonine synthase-like 1 2,073 0,015 
NM_175499 Slitrk6 SLIT and NTRK-like family, member 6 2,071 0,004 
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Gene Number 
Gene 
Symbol Gene Name 
Fold 
Change 
Adjusted 
p-value 
NM_001043355 Map6 microtubule-associated protein 6 2,065 0,008 
A_55_P2041693  n.c. 2,065 0,003 
NM_175686 Prrx1 paired related homeobox 1 2,065 0,003 
BX527063  n.c. 2,063 0,003 
NM_001081407 Plb1 phospholipase B1 2,062 0,003 
AK084291  unclassifiable, full insert sequence 2,061 0,036 
NM_001177574 Gm2022 predicted pseudogene 2022 2,059 0,005 
NM_016919 Col5a3 collagen, type V, alpha 3 2,055 0,012 
NM_001177573  n.c. 2,046 0,005 
NM_007899 Ecm1 extracellular matrix protein 1 2,041 0,005 
DV650784  n.c. 2,039 0,007 
chr5:152006587-
152008784_R 
 n.c. 2,032 0,006 
NM_011607 Tnc tenascin C 2,025 0,006 
NM_027602 Nsun7 NOL1/NOP2/Sun domain family, 
member 7 
2,020 0,004 
chr19:5834117-
5835940_R 
 n.c. 2,015 0,006 
chr4:128727332-
128735227_F 
 n.c. 2,015 0,007 
NM_009866 Cdh11 cadherin 11 2,014 0,004 
NM_007899 Ecm1 extracellular matrix protein 1 2,011 0,003 
NM_028775 Cyp2s1 Mus musculus cytochrome P450, family 
2, subfamily s, polypeptide 1 
2,004 0,005 
 
4.4. 4 weeks, differentially expressed down-regulated genes 
Gene Number 
Gene 
Symbol Gene Name 
Fold 
Change 
Adjusted 
p-value 
chr5:149765314-
149771786_R 
 n.c. 0,483 0,006 
NM_016982 Vpreb1 Mus musculus pre-B lymphocyte gene 
1 
0,434 0,004 
NM_001190325 Igll1 Mus musculus immunoglobulin 
lambda-like polypeptide 1 
0,427 0,003 
NM_009246 Serpina1d serine (or cysteine) peptidase inhibitor, 
clade A, member 1D 
0,478 0,011 
NM_009245 Serpina1c serine (or cysteine) peptidase inhibitor, 
clade A, member 1C 
0,452 0,009 
A_55_P2046709  n.c. 0,474 0,011 
NM_009247 Serpina1e serine (or cysteine) peptidase inhibitor, 
clade A, member 1E 
0,465 0,013 
NM_009243 Serpina1a serine (or cysteine) peptidase inhibitor, 
clade A, member 1A 
0,463 0,014 
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